<?xml version='1.0' encoding='UTF-8' ?><Trials_downloaded_from_ICTRP>
  <Trial>
    <Internal_Number>2452965</Internal_Number>
    <TrialID>EUCTR2004-001298-24-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>An open-label, randomized, multicenter, parallel group study to demonstrate correction of anemia using intravenous injections of RO0503821 in patients with chronic kidney disease who are on dialysis</Public_title>
    <Scientific_title>An open-label, randomized, multicenter, parallel group study to demonstrate correction of anemia using intravenous injections of RO0503821 in patients with chronic kidney disease who are on dialysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          </Scientific_title>
    <Primary_sponsor>F. Hoffmann-La Roche Ltd</Primary_sponsor>
    <Date_registration3>20040628</Date_registration3>
    <Date_registration>28/06/2004</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-001298-24                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>01/07/2004</Date_enrollement>
    <Target_size>168</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Baseline predialysis (for HD patients) Hb concentration 8-11 g/dL determined from the mean of 2 screening values with at least one day between measurements&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Previous therapy with recombinant human erythropoetin or any other erythropoeitc substance within 12 weeks prior to screening. If epoetin treatment has been interrupted for at least 12 weeks, the patient may be enrolled in the study. Ongoing epoetin treatment should not be discontinued to allow participation in the trial.&lt;br&gt;</Exclusion_Criteria>
    <Condition>anemia in chronic kidney patients who are in dialysis</Condition>
    <Intervention>&lt;br&gt;Product Name: cera&lt;br&gt;Product Code: RO 0503821&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: not yet available&lt;br&gt;Other descriptive name: Methoxy polyethilene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;INN or Proposed INN: not yet available&lt;br&gt;Other descriptive name: Methoxy polyethilene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;INN or Proposed INN: not yet available&lt;br&gt;Other descriptive name: Methoxy polyethilene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;INN or Proposed INN: not yet available&lt;br&gt;Other descriptive name: Methoxy polyethilene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 400-&lt;br&gt;INN or Proposed INN: not yet available&lt;br&gt;Other descriptive name: Methoxy polyethilene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1000-&lt;br&gt;&lt;br&gt;Trade Name: Neorecormon&lt;br&gt;Product Name: Neorecormon&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Epoetin beta&lt;br&gt;Other descriptive name: Methoxy polyethilene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50000-&lt;br&gt;INN or Proposed INN: epoetin beta&lt;br&gt;Other descriptive name: Methoxy polyethilene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100000-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To demonstrate the efficay of IV RO 0503821;Secondary Objective: - To asses time to response&lt;br&gt;- To asses the safety and tolerability of multiple doses of RO 0503821 during the correction and extension periods in this patient population&lt;br&gt;- To asses long term safety with RO 0503821 in this patient population&lt;br&gt;- To investigate the farmachokinetics and the concentration-effect relationships after IV administration of RO 0503821 in this patient population;Primary end point(s): To demonstrate the efficay of IV RO 0503821 treatment for correction of anemia in patients with kidney chronic disease who are on dialysis</Primary_outcome>
    <Secondary_ID>BA16736</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2453174</Internal_Number>
    <TrialID>EUCTR2004-002160-22-HU</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety of MK-0431
Monotherapy in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency Who Have Inadequate Glycemic Control - MK-0431 Monotherapy Study in Patients With Type 2 DM and Chronic Renal Insufficiency</Public_title>
    <Scientific_title>A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety of MK-0431
Monotherapy in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency Who Have Inadequate Glycemic Control - MK-0431 Monotherapy Study in Patients With Type 2 DM and Chronic Renal Insufficiency                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Merck &amp; Co., Inc.</Primary_sponsor>
    <Date_registration3>20041012</Date_registration3>
    <Date_registration>12/10/2004</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-002160-22                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>17/11/2004</Date_enrollement>
    <Target_size>90</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;a.	Patient has type 2 diabetes mellitus (T2DM). &lt;br&gt;b.	Patient has moderate, severe, or end-stage renal insufficiency as indicated by a ‘yes’ answer to one or more of the following :&lt;br&gt;1)	Creatinine clearance =30 to &lt; 50 mL/min&lt;br&gt;2)	Creatinine clearance &lt; 30 mL/min&lt;br&gt;3)	Patient receiving dialysis&lt;br&gt;c.	Patient is =18 years of age.&lt;br&gt;d.	Patient has an understanding of the study procedures and agrees to participate in the study by giving written informed consent.&lt;br&gt;e.	Patient is not pregnant or breast-feeding and does not plan to become pregnant for the duration of the study and poststudy follow-up period.&lt;br&gt;f.	Patient is a male, or a female who is highly unlikely to conceive.&lt;br&gt;g.	HbA1c =6.5% and =10% measured at, or within 2 weeks prior to, Visit 3.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;a.	Patient has a history of type 1 diabetes mellitus or a history of ketoacidosis&lt;br&gt;b.	Patient has an ALT or AST &gt;2.0-fold the Upper Limit of Normal (ULN)&lt;br&gt;c.	Patient has acute or rapidly progressive renal disease, or a history of renal transplant.&lt;br&gt;d.	Patient has any of the following disorders within the past 6 months: &lt;br&gt;•	Acute coronary syndrome (e.g., MI or unstable angina).&lt;br&gt;•	Coronary artery intervention (e.g., CABG or PTCA).&lt;br&gt;•	Worsening congestive heart failure (e.g., worsening symptoms or increase in pharmacologic therapy).&lt;br&gt;•	Stroke or transient ischemic neurological disorder.&lt;br&gt;e.	Patient has new or worsening signs or symptoms of coronary heart disease within the past 3 months.&lt;br&gt;f.	Patient has a BMI &lt;20 kg/m2 or &gt;43 kg/m2&lt;br&gt;g.	Patient has a positive urine pregnancy test&lt;br&gt;h.	Patient has any other condition or therapy which, in the opinion of the investigator or Merck medical monitor, might pose a risk to the patient or make participation not in the patient’s best interest.&lt;br&gt;i.	Patient has poor mental function or any other reason to expect that the patient may have difficulty in complying with the requirements of the study.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Type 2 Diabetes Mellitus

Chronic Renal Insufficiency [MedDRA classification code:  10050441] &lt;br&gt;MedDRA version: 7.0
Level: LLT
Classification code 10045242
</Condition>
    <Intervention>&lt;br&gt;Product Name: MK-0431   25-mg Tablet&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;Current Sponsor code: MK-0431&lt;br&gt;Other descriptive name: L-000224715&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: Glibinese [Glipizide 5-mg scored tablets]&lt;br&gt;Product Name: Glibinese 5-mg scored tablets&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: glipizide&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: In patients with type 2 diabetes mellitus and chronic renal insufficiency with inadequate glycemic control&lt;br&gt;&lt;br&gt;Primary:  To assess the safety and tolerability of MK-0431 after 12 weeks.&lt;br&gt;;Secondary Objective: In patients with type 2 diabetes mellitus and chronic renal insufficiency with inadequate glycemic control&lt;br&gt;&lt;br&gt;To assess the safety and tolerability of MK-0431 over 54 weeks.;Primary end point(s): N/A</Primary_outcome>
    <Secondary_ID>0431-028</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2453243</Internal_Number>
    <TrialID>EUCTR2004-000587-26-HU</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A 24-month Extension to a one-year, multicentre, double-blinded, double-dummy, randomized study to evaluate the safety and efficacy of two doses of FTY720 combined with full-dose Neoral and steroids versus Cellcept combined with full-dose Neoral and steroids, in de novo adult renal transplant recipients.</Public_title>
    <Scientific_title>A 24-month Extension to a one-year, multicentre, double-blinded, double-dummy, randomized study to evaluate the safety and efficacy of two doses of FTY720 combined with full-dose Neoral and steroids versus Cellcept combined with full-dose Neoral and steroids, in de novo adult renal transplant recipients.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Novartis Pharma Services AG</Primary_sponsor>
    <Date_registration3>20041110</Date_registration3>
    <Date_registration>10/11/2004</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000587-26                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>01/02/2005</Date_enrollement>
    <Target_size>690</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: yes&lt;br&gt;Other trial design description: Partially double blinded, partially open&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;a)	The patient has given written informed consent to participate in the extension study.&lt;br&gt;b)	The patient has completed the core study (through 12 months post-transplantation, either being maintained on study medication or having attended the Follow-up visits up to Month 12 after being discontinued from study medication).  &lt;br&gt;c)	Females capable of becoming pregnant are required to practice a medically approved method of birth control as long as they are on study medication and for a period of 3 months following discontinuation of study medication.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Patients with any medical or psychosocial condition which the investigator believes would hinder compliance with the study requirements.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Prophylaxis of kidney allograft rejection in de novo adult renal transplant recipients &lt;br&gt;MedDRA version: 7.0
Level: LLT
Classification code 10023439
</Condition>
    <Intervention>&lt;br&gt;Product Name: FTY720&lt;br&gt;Product Code: FTY720&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: CellCept&lt;br&gt;Product Name: Mycophenolate Mofetil&lt;br&gt;Product Code: RS-61443&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: Sandimmun Neoral&lt;br&gt;Product Name: Ciclosporin for microemulsion&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The objective of this extension is to assess long-term safety and efficacy data of two doses of FTY720 (2.5 or 5.0 mg) combined with full dose Neoral and steroids versus MMF combined with full dose Neoral and steroids in de novo adult renal transplant recipients beyond 12 months post-transplantation.;Secondary Objective: To provide continued treatment for patients who have completed the 12-month core study on study medication.;Primary end point(s): Biopsy-proven acute rejection, graft loss, death or discontinuation from study</Primary_outcome>
    <Secondary_ID>CFTY720A2218E1</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2453302</Internal_Number>
    <TrialID>EUCTR2004-004416-22-SE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Platelet function in diabetic patients without and with renal impairment, and the effects of lipid-lowering treatment</Public_title>
    <Scientific_title>Platelet function in diabetic patients without and with renal impairment, and the effects of lipid-lowering treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>Karolinska Institutet, Dept of Medicine, Clinical Pharmacology Unit</Primary_sponsor>
    <Date_registration3>20041206</Date_registration3>
    <Date_registration>06/12/2004</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-004416-22                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>05/01/2005</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: yes&lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: yes&lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Diabetes mellitus type 2&lt;br&gt;&lt;br&gt;With or without established microalbuminuria (urinary albumin excretion of 30-299 µg/mg creatinine in a spot sample) Two out of three specimens collected within a 3-6 month period should be abnormal before the diagnosis can be settled. &lt;br&gt;&lt;br&gt;Glomerular filtration rate (GFR) between 15-50 ml/min (measured the last 6 months) or GFR &gt;75ml/min. GFR will be established by 24-hour Iohexolclearence.&lt;br&gt;&lt;br&gt;Age 18-80 years&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Definite history of myocardial infarction, coronary revascularisation procedure or stroke. (i.e, a strong clinical indication for statin treatment) &lt;br&gt;&lt;br&gt;Functioning renal transplant, or living donor-related transplant planned.&lt;br&gt;&lt;br&gt;Patients on dialysis.&lt;br&gt;&lt;br&gt;Poor metabolic control, i.e HbA1c &gt; 9%&lt;br&gt;&lt;br&gt;Definite history of chronic liver disease, or abnormal liver function (i.e ALT &gt;1,5 x ULN or, if ALT not available, AST &gt; 1,5 x ULN). &lt;br&gt;&lt;br&gt;Evidence of active inflammatory muscle disease (e.g dermatomyositis, polymyositis), or CK&gt;3 x ULN&lt;br&gt;&lt;br&gt;Definite previous adverse reaction to a statin or to ezetimibe&lt;br&gt;&lt;br&gt;Definite previous adverse reaction to acetylsalicylic acid.&lt;br&gt;&lt;br&gt;Definite previous adverse reaction to an ACE-inhibitor.&lt;br&gt;&lt;br&gt;Need for concomitant treatment with a strong inhibitor of CYP3A4, such as itrokonazole, ketokonazole, erythromycin, clarithromycin, HIV-protease inhibitors or nefazodone (i.e. agents that may markedly elevate simvastatin levels).&lt;br&gt;&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Diabetes mellitus type 2, without or with renal impairment
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Zocord  R&lt;br&gt;Product Name: Zocord  R&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Simvastatin&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration number: 40-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;Trade Name: Ezetrol&lt;br&gt;Product Name: Ezetrol  R&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: ezetimibe&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration number: 10-&lt;br&gt;Pharmaceutical form of the placebo: Tablet&lt;br&gt;Route of administration of the placebo: Oral use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To compare the effects of simvastatin + ezetimibe with those of simvastatin alone, on thrombogenic mechanisms, in patients with diabetes mellitus type 2.;Secondary Objective: a) Compare the effects of simvastatin alone with those of placebo (baseline data) on thrombogenic mechanisms&lt;br&gt;b) Compare the effects of simvastatin + ezetimibe with those of simvastatin alone, and simvastatin alone with placebo on inflammatory variables.&lt;br&gt;c) Assess how the treatment effects relate to renal function.  &lt;br&gt;;Primary end point(s): ADP stimulated platelet P-selectin expression (flow cytometry in whole blood).&lt;br&gt;Other flow cytometric platelet variables related to the primary end point are (a) circulating platelet-platelet aggregates, (b) circulating platelet-leukocyte aggregates, (c) single platelet counts.&lt;br&gt;</Primary_outcome>
    <Secondary_ID>DMK001</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2453351</Internal_Number>
    <TrialID>EUCTR2004-002032-26-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>An open-label, multi-center study to document the efficacy, safety and tolerability of long-term administration of RO0503821 in patients with chronic renal anemia</Public_title>
    <Scientific_title>An open-label, multi-center study to document the efficacy, safety and tolerability of long-term administration of RO0503821 in patients with chronic renal anemia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              </Scientific_title>
    <Primary_sponsor>F. Hoffmann-La Roche Ltd.</Primary_sponsor>
    <Date_registration3>20041112</Date_registration3>
    <Date_registration>12/11/2004</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-002032-26                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>23/12/2004</Date_enrollement>
    <Target_size>1000</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Aranesp, NeoRecormon&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	1.	Written informed consent&lt;br&gt;2.	Adult patients (equal or more than 18 years old) with chronic renal anemia&lt;br&gt;3.	Continuous maintenance erythropoietic therapy with RO0503821 or a protocol-specified reference medication (epoetin alfa formulated with human albumin,  epoetin beta or darbepoetin alfa) in one of the following studies: BA16528, BA16285, BA16286, BA16736, BA16738, BA16739, BA16740, BA17283 and BA17284&lt;br&gt;4.	Hemoglobin concentration between 10.5 and 13.0 g/dL &lt;br&gt;5.	Adequate iron status defined as serum ferritin equal or more than 100 ng/mL or TSAT equal or more than 20% (or percentage of hypochromic RBCs &lt; 10%)&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;6.	Poorly controlled hypertension necessitating interruption of erythropoietin treatment in the 6 months before screening&lt;br&gt;7.	Epileptic seizure in the  6 months before screening&lt;br&gt;8.	Platelets  &gt; 500 x 10 9/L&lt;br&gt;9.	Pure red cell aplasia &lt;br&gt;10.	Chronic congestive heart failure (New York Heart Association Class IV)&lt;br&gt;11.	High likelihood of early withdrawal or interruption of the study (e.g., myocardial infarction, severe or unstable coronary artery disease, stroke, severe liver disease within the 12 weeks before screening)&lt;br&gt;12.	Active malignant disease (except non-melanoma skin cancer)&lt;br&gt;13.	Life expectancy less than 12 months&lt;br&gt;14.	Pregnancy or breast-feeding&lt;br&gt;15.	Women of childbearing potential without effective contraception&lt;br&gt;16.	Administration of another investigational drug planned during the study period&lt;br&gt;17.	Known hypersensitivity to recombinant human erythropoietin, polyethylene glycol or to any constituent of the study or reference drug  formulations&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patient with chronic renal anaemia</Condition>
    <Intervention>&lt;br&gt;Product Name: N/A&lt;br&gt;Product Code: RO0503821&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: not available yet&lt;br&gt;Other descriptive name: Methoxy polyethylene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50-&lt;br&gt;INN or Proposed INN: not available yet&lt;br&gt;Other descriptive name: Methoxy polyethylene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;INN or Proposed INN: not available yet&lt;br&gt;Other descriptive name: Methoxy polyethylene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 200-&lt;br&gt;INN or Proposed INN: not available yet&lt;br&gt;Other descriptive name: Methoxy polyethylene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 400-&lt;br&gt;INN or Proposed INN: not available yet&lt;br&gt;Other descriptive name: Methoxy polyethylene glycol-epoetin beta&lt;br&gt;Concentration unit: µg/ml microgram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1000-&lt;br&gt;&lt;br&gt;Trade Name: NeoRecormon&lt;br&gt;Product Name: NeoRecormon &lt;br&gt;Pharmaceutical Form: Powder and solvent for solution for injection&lt;br&gt;INN or Proposed INN: Epoetin beta&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 50.000-&lt;br&gt;INN or Proposed INN: Epoetin beta&lt;br&gt;Concentration unit: IU international unit(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100.000-&lt;br&gt;&lt;br&gt;Trade Name: Aranesp&lt;br&gt;Product Name: Aranesp&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Darbepoetin alfa&lt;br&gt;Concentration unit: µg microgram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 15-&lt;br&gt;INN or Proposed INN: Darbepoetin alfa&lt;br&gt;Concentration unit: µg microgram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20-&lt;br&gt;INN or Proposed INN: Darbepoetin alfa&lt;br&gt;Concentration unit: µg microgram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 30-&lt;br&gt;INN or Proposed INN: Da</Intervention>
    <Primary_outcome>Main Objective: To document that RO0503821 administered for prolonged periods is efficacious, safe and well tolerated in patients treated for  chronic renal anemia;Secondary Objective: N/A;Primary end point(s): Analysis of Efficacy&lt;br&gt;No formal efficacy assessment will be performed. Efficacy parameters such as hemoglobin will be reported descriptively using means, standard deviations and percentiles.&lt;br&gt;&lt;br&gt;Analysis of Safety &lt;br&gt;All patients who have received at least one dose of RO0503821 or of reference medication and a safety follow-up, whether withdrawn prematurely or not, will be included in the safety analysis. The safety parameters will be vital signs, AEs and the safety laboratory parameters. &lt;br&gt;All safety parameters will be summarized descriptively. Vital signs and laboratory data will be assessed for clinically relevant abnormalities.&lt;br&gt;Frequencies and incidence rates of AEs will be tabulated.  The goal of the statistical evaluation of AE data is a standardized tabulation of the frequencies and incidence rates of all observed AEs. These will be calculated on a per-patient basis rather than on an event basis. &lt;br&gt;Brief narratives will describe each death, each drug related SAE, premature withdrawals arising from AEs, and other significant AEs that are judged to be of special interest because of clinical importance. &lt;br&gt;All safety parameters will be summarized descriptively. Vital signs and laboratory data will be assessed for clinically relevant abnormalities.</Primary_outcome>
    <Secondary_ID>BH 18387</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2453504</Internal_Number>
    <TrialID>EUCTR2004-002310-10-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Study to Investigate Cinacalcet Treatment in Haemodialysis Patients with Secondary Hyperparathyroidism - SENSOR</Public_title>
    <Scientific_title>Study to Investigate Cinacalcet Treatment in Haemodialysis Patients with Secondary Hyperparathyroidism - SENSOR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Amgen Development Europe</Primary_sponsor>
    <Date_registration3>20041110</Date_registration3>
    <Date_registration>10/11/2004</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-002310-10                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>17/11/2004</Date_enrollement>
    <Target_size>800</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;- CKD patients requiring dialysis (HD, HDF, HF) for at least 1 month before enrolment&lt;br&gt;- Males or females = 18 years of age at the time of informed consent. &lt;br&gt;- Men and women participating in this study must agree to use, in the opinion of the principal investigator, highly effective contraceptive measures throughout the study.  Females must have a negative serum pregnancy test (or definitive evidence to demonstrate lack of pregnancy) within 30 days before randomisation, unless there is a definite history of amenorrhoea.&lt;br&gt;- An iPTH determination within 14 days before randomisation must be = 300 pg/mL (biPTH = 150 pg/mL).  &lt;br&gt;- A serum calcium determination (corrected for calcium) within 14 days before randomisation must be = 8.4 mg/dL [2.1 mmol/L].  &lt;br&gt;- Signed the Independent Ethics Committee (IEC) approved Informed Consent document, before any study specific procedures are initiated &lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;- Have an unstable medical condition, defined as having been hospitalised, other than for dialysis vascular access revision, within 30 days before day 1, or otherwise unstable in the judgment of the investigator.&lt;br&gt;- Are currently breast-feeding.&lt;br&gt;- Are performing peritoneal dialysis&lt;br&gt;- Have had a parathyroidectomy in the 3 months before day 1.&lt;br&gt;- Are currently enrolled in, or have not yet completed at least 30 days before day 1 other invasive investigational device or investigational drug trials, or are receiving other investigational agents (experimental dialysis machines are acceptable).&lt;br&gt;- Have a gastrointestinal disorder that may be associated with impaired absorption of orally administered medications or an inability to swallow tablets.&lt;br&gt;- Have a disorder that would interfere with understanding and giving informed consent or compliance with protocol requirements&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Secondary hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) on dialysis</Condition>
    <Intervention>&lt;br&gt;Product Name: Cinacalcet&lt;br&gt;Product Code: AMG 073&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Cinacalcet&lt;br&gt;CAS Number: 364782-34-3&lt;br&gt;Current Sponsor code: AMG 073&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 30-&lt;br&gt;&lt;br&gt;Product Name: Cinacalcet&lt;br&gt;Product Code: AMG 073&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Cinacalcet&lt;br&gt;CAS Number: 364782-34-3&lt;br&gt;Current Sponsor code: AMG 073&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 60-&lt;br&gt;&lt;br&gt;Product Name: Cinacalcet&lt;br&gt;Product Code: AMG 073&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Cinacalcet&lt;br&gt;CAS Number: 364782-34-3&lt;br&gt;Current Sponsor code: AMG 073&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 90-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To demonstrate that the efficacy of cinacalcet when co-administered with the first meal after dialysis is comparable (non-inferior) to the efficacy of cinacalcet when administered during the dialysis study visit.;Secondary Objective: To evaluate the safety of cinacalcet when co-administered with the first major meal after dialysis.&lt;br&gt;To evaluate a predefined strategy to manage nausea/vomiting during the study&lt;br&gt;;Primary end point(s): The proportion of subjects with a mean iPTH £ 300 pg/mL at weeks 11 and 13</Primary_outcome>
    <Secondary_ID>20040143</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2453669</Internal_Number>
    <TrialID>EUCTR2004-004488-31-NO</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Does cyclosporine A reduce the insulin secretion from the pancreas?</Public_title>
    <Scientific_title>Does cyclosporine A reduce the insulin secretion from the pancreas?                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Rikshospitalet University Hospital, University of Oslo</Primary_sponsor>
    <Date_registration3>20050201</Date_registration3>
    <Date_registration>01/02/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-004488-31                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement />
    <Target_size>16</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;Other trial design description: Therapy followed by wash out&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Dialysis patients planned to be kidney transplanted and not treated with steroids&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Age above 75 years or below 18 years&lt;br&gt;Pregnancy&lt;br&gt;Lactating mothers&lt;br&gt;Diabetes mellitus&lt;br&gt;Less than 2 months of dilayses&lt;br&gt;Coronary heart disease&lt;br&gt;Ongoing corticosteroid treatment&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Kidney failure / dialysis patients / transplantation</Condition>
    <Intervention>&lt;br&gt;Trade Name: Sandimmun Neoral&lt;br&gt;Product Name: Sandimmun Neoral&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;Current Sponsor code: NOVARTIS&lt;br&gt;Other descriptive name: Sandimmun Neoral&lt;br&gt;Concentration unit: µg/l microgram(s)/litre&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 150-200&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;Other descriptive name: cyclosporine A&lt;br&gt;Concentration unit: µg/l microgram(s)/litre&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 150-200&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Test the effect of cyclosporine A on insulin release;Secondary Objective: Test the effect of cyclosporine A on insulin action, endothelial function. Test the useage of pretransplant cyclosporine A pharmacokinetics detrminations for dose individualisation at the time of transplantation;Primary end point(s): Change in insulin secretion&lt;br&gt;</Primary_outcome>
    <Secondary_ID>S-02005</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2453918</Internal_Number>
    <TrialID>EUCTR2004-001608-11-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A Multi-centre, Open Label, Randomised, Parallel Group Pilot Study to assess the Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis for End Stage Renal Disease</Public_title>
    <Scientific_title>A Multi-centre, Open Label, Randomised, Parallel Group Pilot Study to assess the Efficacy and Safety of Lanthanum Carbonate and Sevelamer Hydrochloride in Patients Receiving Haemodialysis for End Stage Renal Disease                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>Shire Pharmaceutical Development Ltd</Primary_sponsor>
    <Date_registration3>20050303</Date_registration3>
    <Date_registration>03/03/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-001608-11                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>18/11/2004</Date_enrollement>
    <Target_size>60</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Male or female patients greater than or equal to 18 years of age receiving haemodialysis for end stage renal disease with a level of serum phosphate&gt;5.9mg/dL (1.9mmol/L) after washout or sub-optimally treated with current phosphate binder. Patients (including those who have undergone renal transplantation in the past) must have received haemodialysis for chronic renal failure three times per week for at least the previous two months. &lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Pregnant or lactating women. Patients with screening calcium below 8.8mg/dL (2.2mmol/L) or with significant abnormal laboratory values (excluding markers of pathologies associated with chronic renal failure), which in the opinion of the investigator should exclude the patient from the study. Patients with clinically significant uncontrolled concurrent illness a life threatening malignancy or current multiple myeloma or known to be HIV positive. Patients with any significant bowel obstruction, active inflammatory disease, gastrointestinal (GI) motility disorders, abnormal or irregular bowel motion or a history of major GI surgery within the last 6 mnths. Patients who have been in any other clinical trial within the last 30 days or who have previously taken lanthanum carbonate in the last year. &lt;br&gt;</Exclusion_Criteria>
    <Condition>Hyperphosphataemia in Patients Receiving Haemodialysis for End Stage Renal Disease</Condition>
    <Intervention>&lt;br&gt;Product Name: Lanthanum Carbonate &lt;br&gt;Product Code: SPD 405&lt;br&gt;Pharmaceutical Form: Chewable tablet&lt;br&gt;INN or Proposed INN: Lanthanum (III) carbonate hydrate &lt;br&gt;Current Sponsor code: SPD 405&lt;br&gt;Other descriptive name: Lanthanum carbonate hydrate&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;Product Name: Lanthanum Carbonate &lt;br&gt;Product Code: SPD 405&lt;br&gt;Pharmaceutical Form: Chewable tablet&lt;br&gt;INN or Proposed INN: Lanthanum (III) carbonate hydrate &lt;br&gt;Current Sponsor code: SPD 405&lt;br&gt;Other descriptive name: Lanthanum carbonate hydrate&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration number: 500-&lt;br&gt;&lt;br&gt;Product Name: Lanthanum Carbonate &lt;br&gt;Product Code: SPD 405&lt;br&gt;Pharmaceutical Form: Chewable tablet&lt;br&gt;INN or Proposed INN: Lanthanum (III) carbonate hydrate &lt;br&gt;Current Sponsor code: SPD 405&lt;br&gt;Other descriptive name: Lanthanum carbonate hydrate&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration number: 750-&lt;br&gt;&lt;br&gt;Product Name: Lanthanum Carbonate &lt;br&gt;Product Code: SPD 405&lt;br&gt;Pharmaceutical Form: Chewable tablet&lt;br&gt;INN or Proposed INN: Lanthanum (III) carbonate hydrate &lt;br&gt;Current Sponsor code: SPD 405&lt;br&gt;Other descriptive name: Lanthanum carbonate hydrate&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration number: 1000-&lt;br&gt;&lt;br&gt;Trade Name: Renagel 800mg Film Coated Tablets &lt;br&gt;Product Name: Renagel &lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Sevelamer &lt;br&gt;Concentration unit: mg/g milligram(s)/gram&lt;br&gt;Concentration number: 800-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To assess phosphate reduction and control (3.5-5.5mg/dL [1.1-1.8mmol/L]) in patients with End Stage Renal Disease (ESRD) following administration of lanthanum carbonate or sevelamer hydrochloride;Secondary Objective: To assess: &lt;br&gt;The effects of lanthanum carbonate and sevelamer hydrochloride on serum calcium and calcium phosphate product levels&lt;br&gt;The percentage of patients achieving a reduction in serum calcium-phosphate product to less than or equal to 4.4 (mmol/L)2 (54.56mg2/dL2) following administration of lanthanum carbonate or sevelamer hydrochloride&lt;br&gt;Average daily pill burden, dose levels and compliance&lt;br&gt;The safety and tolerability of lanthanum carbonate&lt;br&gt;Patient satisfaction with treatment ;Primary end point(s): Serum phosphate reduction and control rate (defined as 3.5-5.5mg/dL [1.1-1.8 mmol/L])</Primary_outcome>
    <Secondary_ID>SPD405-310</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2454519</Internal_Number>
    <TrialID>EUCTR2005-000087-12-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Estudio multicéntrico, aleatorizado, doble ciego, de grupos paralelos, en fase IV, para comparar los efectos renales del medio de contraste no iónico isosmolar, iodixanol 320 mg I/ml (VisipaqueTM), con el medio de contraste no iónico de baja osmolaridad, iopamidol 300 mg I/ml, en sujetos con insuficiencia renal y diabetes mellitus sometidos a TC helicoidal multidetector.</Public_title>
    <Scientific_title>Estudio multicéntrico, aleatorizado, doble ciego, de grupos paralelos, en fase IV, para comparar los efectos renales del medio de contraste no iónico isosmolar, iodixanol 320 mg I/ml (VisipaqueTM), con el medio de contraste no iónico de baja osmolaridad, iopamidol 300 mg I/ml, en sujetos con insuficiencia renal y diabetes mellitus sometidos a TC helicoidal multidetector.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </Scientific_title>
    <Primary_sponsor>Amersham Health S.A. (parte de GE Healthcare Ltd y sus filiales)</Primary_sponsor>
    <Date_registration3>20050608</Date_registration3>
    <Date_registration>08/06/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-000087-12                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>16/08/2005</Date_enrollement>
    <Target_size>500</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.) The subject is at least 18 years old.&lt;br&gt;2.) The subject has diabetes mellitus (type I or II), treated with insulin or oral antidiabetic agents for at least 1 year.&lt;br&gt;3.) The subject has a pre-study serum creatinine = 1.7 mg/dl (150 µmol/l) if a man, or = 1.5 mg/dl (133 µmol/l) if a woman,&lt;br&gt;or an estimated pre-study glomerular filtration rate (eGFR) = 50 mL/min/1.73m2 according to the Modification of Diet in Renal Disease (MDRD) equation.*&lt;br&gt;The pre-study serum creatinine value must not be older than 3 months and any acute causes of impaired renal function have to be ruled out.&lt;br&gt;* the four-component MDRD equation provides estimates of GFR standardised for body surface, based on the variables serum creatinine concentration (SCr), age, race, and sex:&lt;br&gt;eGFR (mL/min/1.73m2) = 186 x SCr-1.154 x age-0.203 (x 0.742 if female) (x 1.210 if black)&lt;br&gt;Pre-study serum creatinine has to be expressed in milligrams per decilitre, age in years.&lt;br&gt;4.) The subject is referred for a contrast-enhanced MDCT examination, using a standardised CM volume of 1.5 mL per kilogram of body weight and an injection rate of 4 mL/s (in cases with inadequate venous access, a flow of 3 mL/s may be applied). For subjects with a body weight exceeding 100 kilogram, a total CM volume of 150 mL should be administered.&lt;br&gt;5.) The subject is a man, or a woman who is either surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), postmenopausal (with cessation of menses for more than 1 year), or, if of child-bearing potential, the result of a urine or serum ?-HCG pregnancy test conducted at screening must be known to be negative before IMP administration.&lt;br&gt;6.) The subject is able and willing to comply with study procedures.&lt;br&gt;7.) Signed and dated (i.e., date and time) written informed consent is obtained.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.) The subject is pregnant or lactating.&lt;br&gt;2.) The subject was previously included in this study.&lt;br&gt;3.) The subject has received another IMP within 30 days before or is scheduled to receive one within 7 days after IMP administration.&lt;br&gt;4.) The subject has received iodinated contrast medium within 7 days before or will receive one within 7 days after IMP administration.&lt;br&gt;5.) The subject has a history of serious hypersensitivity reaction to iodinated contrast media.&lt;br&gt;6.) The subject has non-compensated heart failure (NYHA III or IV).&lt;br&gt;7.) The subject has manifest thyrotoxicosis.&lt;br&gt;8.) The subject is in acute renal failure or in acute on chronic renal failure.&lt;br&gt;9.) The subject has undergone kidney transplantation.&lt;br&gt;10.) The subject is on haemodialysis or peritoneal dialysis.&lt;br&gt;11.) The subject has liver cirrhosis with ascites.&lt;br&gt;12.) The subject has multiple myeloma.&lt;br&gt;13.) The subject is haemodynamically unstable pre-study.&lt;br&gt;14.) The subject is scheduled for major surgery within 7 days after IMP administration.&lt;br&gt;15.) The subject has received or will receive any of the following potentially nephroprotective drugs from 3 days before until 7 days after IMP administration:&lt;br&gt;n-acetylcysteine, fenoldopam, dopamine, or hydration with sodium bicarbonate. Concurrent medication with other drugs that are potentially nephroprotective, like calcium channel blockers or theophylline, are permitted provided they are used for the subject’s underlying disease (e.g., cardiac disease, arterial hypertension, bronchial asthma).&lt;br&gt;16.) The subject has received nephrotoxic drugs within 7 days before or will receive such drugs within 7 days after IMP administration. Respective nephrotoxic drugs include antibiotics (e.g., aminoglycosides, vancomycin, amphotericin B), antineoplastic agents (e.g., methotrexate, cisplatin), and immunosuppressants (e.g., cyclosporine).&lt;br&gt;17.) The subject has received nonsteroidal anti-inflammatory drugs (NSAID) within 3 days before or will receive such drugs within 7 days after IMP administration, with the exception of low dose aspirin (up to 325 mg per day). However, subjects who are on a stable NSAID regimen may be enrolled.&lt;br&gt;18.) The subject has had or is planned to have the initiation, discontinuation, or change in dose of any of the following from 3 days before until 7 days after IMP administration: trimethoprim, cimetidine, angiotensin converting enzyme inhibitors, or angiotensin receptor blockers.&lt;br&gt;&lt;br&gt;19.) The subject is on metformin treatment at the time of the study procedure: metformin administration has to be discontinued prior to IMP administration, according to local guidelines, withheld for at least 48 hours, and resumed only if renal function / serum creatinine did not worsen compared to the baseline values.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Subjects with a combination of diabetes mellitus (type I or II), and impaired renal function.

 &lt;br&gt;MedDRA version: 7.0
Level: Pt
Classification code 10061835
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Visipaque 320 mgI/ml &lt;br&gt;Product Name: Visipaque 320 mg I/ml&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Iodixanol&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 320 mg I/ml-&lt;br&gt;&lt;br&gt;Trade Name: Iopamiro 300 mg I/ml&lt;br&gt;Product Name: Iopamiro&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Iopamidol&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 300 mg I/ml-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To evaluate and compare the effects of two different contrast media, iodixanol 320 mg I/mL and iopamidol 300 mg I/mL, on renal function;Secondary Objective: To evaluate and compare the safety profile of iodixanol 320 mg I/mL and iopamidol 300 mg I/mL&lt;br&gt;To evaluate and compare the efficacy of iodixanol 320 mg I/mL and iopamidol 300 mg I/mL&lt;br&gt;;Primary end point(s): The primary endpoint will be the incidence rate of contrast-induced nephropathy (CIN), defined as an intra-individual increase in serum creatinine of at least 44.2 µmol/l (0.5 mg/dl) from baseline up to day 3.&lt;br&gt;&lt;br&gt;</Primary_outcome>
    <Secondary_ID>DXV406</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2454536</Internal_Number>
    <TrialID>EUCTR2005-001231-29-SE</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A PROSPECTIVE, RANDOMISED, PLACEBO CONTROLLED, MULTI-CENTER STUDY 
OF THE EFFICACY AND SAFETY OF RITUXIMAB AS INDUCTION THERAPY TOGETHER WITH TACROLIMUS, MYCOPHENOLATE MOFETIL AND STEROIDS FOR PATIENTS UNDERGOING RENAL TRANSPLANTATION
</Public_title>
    <Scientific_title>A PROSPECTIVE, RANDOMISED, PLACEBO CONTROLLED, MULTI-CENTER STUDY 
OF THE EFFICACY AND SAFETY OF RITUXIMAB AS INDUCTION THERAPY TOGETHER WITH TACROLIMUS, MYCOPHENOLATE MOFETIL AND STEROIDS FOR PATIENTS UNDERGOING RENAL TRANSPLANTATION
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Dept of Transplantation Surgery B 56, Karolinska University Hospital, Huddinge</Primary_sponsor>
    <Date_registration3>20050705</Date_registration3>
    <Date_registration>05/07/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-001231-29                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>08/09/2005</Date_enrollement>
    <Target_size>140</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients aged 18 years or above&lt;br&gt;Recipients of first or second renal transplant&lt;br&gt;Recipients from living or cadaveric donors&lt;br&gt;Single organ recipients (kidney only)&lt;br&gt;Patients providing written informed consent&lt;br&gt;Patients cooperative and able to complete all the assessment procedures&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;HLA-identical siblings&lt;br&gt;Patients receiving immunosuppressive therapy within the preceding 28 days&lt;br&gt;PRA &gt;50% within 6 months prior to enrolment&lt;br&gt;Previous exposure to murine antibodies&lt;br&gt;History of malignancy (except localised non-melanotic skin cancer) or the presence of any active malignancy at the time of transplant&lt;br&gt;Active infection (HCV, HBV, HIV)&lt;br&gt;Pregnant or lactating females &lt;br&gt;Women of child bearing potential not willing to use reliable form of contraception                                                                                                       &lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Chronic renal failure patients who are receiving a kidney transplant.  Different immunosuppressive protocls are awailable. However, current strategies for the medical management of transplant patients are largely focused on the prevention and treatment of T-cell mediated processes. However, there is an increasing evidence that B cells may significantly contribute to post-transplant morbidity in addition to their role in acute humoral rejection.</Condition>
    <Intervention>&lt;br&gt;Trade Name: MabThera&lt;br&gt;Product Name: Mabthera&lt;br&gt;Product Code: RO 45-2294/V02&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;Pharmaceutical form of the placebo: Solution for infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The primary objective of the study is to determine the effect of one dose of rituximab as induction therapy together with a conventional tacrolimus, mycophenolate mofetil, prednisolone immunosuppressive protocol on the incidence of treatment failure (biopsy-proven acute rejection, graft loss or death) at 6 months post transplant. &lt;br&gt;&lt;br&gt;;Secondary Objective: To assess the effect of rituximab induction on renal function at 6 months post transplant, measured as creatinine clearance. &lt;br&gt;&lt;br&gt;To assess the incidence and severity of  infections (CMV, BKV, fungal and bacterial) in the two groups. &lt;br&gt;Creatinine clearance determined by the iohexol technique at 6 months &lt;br&gt;Incidence of opportunistic infections (CMV, BK, fungus)&lt;br&gt;Incidence of urinary tract infections and septicemia &lt;br&gt;Incidence of rituximab-related adverse events&lt;br&gt;Incidence of malignancies &lt;br&gt;All adverse events including clinically significant abnormalities and clinical and laboratory parameters&lt;br&gt;&lt;br&gt;Additional parameters to be assessed peroperatively and at 6 months&lt;br&gt;Number of CD19+, CD20+ lymphocytes in blood &lt;br&gt;Immunoglobulin G and M levels&lt;br&gt;Anti-tetanus IgG&lt;br&gt;Anti-CMV IgG&lt;br&gt;Cystatin C &lt;br&gt;Iohexol clearance (at 6 months only)&lt;br&gt;Transplant biopsy&lt;br&gt;&lt;br&gt;&lt;br&gt;;Primary end point(s): The primary endpoint will be a composite endpoint defined as treatment failure,&lt;br&gt;including the occurrence of any of the following: biopsy-proven acute rejection, graft loss or death during the first 6 months following transplantation. &lt;br&gt;</Primary_outcome>
    <Secondary_ID>2005-01-02</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2454693</Internal_Number>
    <TrialID>EUCTR2004-002973-22-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Epidemiological open-label study to evaluate the frequency of helicobacter Pylori infections prior to and after equimolar switch from therapy with MMF to enteric-coated Mycophenolic Acid (MYFORTIC-ERL080) in stable renal transplant patients</Public_title>
    <Scientific_title>Epidemiological open-label study to evaluate the frequency of helicobacter Pylori infections prior to and after equimolar switch from therapy with MMF to enteric-coated Mycophenolic Acid (MYFORTIC-ERL080) in stable renal transplant patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>AZIENDA UNIVERSITARIA OSPEDALE POLICLINICO UMBERTO I</Primary_sponsor>
    <Date_registration3>20050801</Date_registration3>
    <Date_registration>01/08/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-002973-22                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>28/04/2004</Date_enrollement>
    <Target_size>250</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;</Exclusion_Criteria>
    <Condition>Profilaxis of rejection in stable renal transplant patients &lt;br&gt;MedDRA version: 6.1
Level: PT
Classification code 10046694
</Condition>
    <Intervention>&lt;br&gt;Product Name: NA&lt;br&gt;Product Code: NA&lt;br&gt;Pharmaceutical Form: Film-coated tablet&lt;br&gt;INN or Proposed INN: Mycophenolic acid&lt;br&gt;CAS Number: 115007-34-6&lt;br&gt;Current Sponsor code: ERL080&lt;br&gt;Other descriptive name: NA&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 180-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: ;Secondary Objective: ;Primary end point(s): </Primary_outcome>
    <Secondary_ID>CERL080AIT03</Secondary_ID>
    <Secondary_Sponsor>AZIENDA POLICLINICO UMBERTO I</Secondary_Sponsor>
  </Trial>
  <Trial>
    <Internal_Number>2454739</Internal_Number>
    <TrialID>EUCTR2005-000855-14-IT</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Multicenter, not controlled, prospectic clinical phase IV study: safety and efficacy of an immunosuppressive regimen with Thymoglobuline and Rapamune in patients receiving a renal transplantation from a marginal donor.</Public_title>
    <Scientific_title>Multicenter, not controlled, prospectic clinical phase IV study: safety and efficacy of an immunosuppressive regimen with Thymoglobuline and Rapamune in patients receiving a renal transplantation from a marginal donor.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>AZIENDA OSPEDALIERA DI PADOVA</Primary_sponsor>
    <Date_registration3>20050810</Date_registration3>
    <Date_registration>10/08/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-000855-14                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>18/07/2005</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;</Exclusion_Criteria>
    <Condition>Acute rejection prophylaxis after single-double kidney transplantation from marginal donors making use of a not nephrotoxic immunosuppressive regimen. &lt;br&gt;MedDRA version: 6.1
Level: PT
Classification code 10023439
</Condition>
    <Intervention>&lt;br&gt;Trade Name: RAPAMUNE*1MG 100 CPR&lt;br&gt;Product Name: NA&lt;br&gt;Product Code: NA&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Sirolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: RAPAMUNE*2MG 30 CPR&lt;br&gt;Product Name: NA&lt;br&gt;Product Code: NA&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Sirolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 2-&lt;br&gt;&lt;br&gt;Trade Name: RAPAMUNE*OS 60 ML 1 MG&lt;br&gt;Product Name: NA&lt;br&gt;Product Code: NA&lt;br&gt;Pharmaceutical Form: Oral solution&lt;br&gt;INN or Proposed INN: Sirolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: THYMOGLOBULINE*IV 1F 25MG +F&lt;br&gt;Product Name: NA&lt;br&gt;Product Code: NA&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: Antithymocyte immunoglobulin (rabbit)&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 25-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: ;Secondary Objective: ;Primary end point(s): </Primary_outcome>
    <Secondary_ID>01-865-2005</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2454772</Internal_Number>
    <TrialID>EUCTR2005-002380-90-DK</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Effekten af intravenøs infusion af n-3 polyumættede fedtsyrer på risikomarkører for pludselig hjertedød hos hæmodialysepatienter</Public_title>
    <Scientific_title>Effekten af intravenøs infusion af n-3 polyumættede fedtsyrer på risikomarkører for pludselig hjertedød hos hæmodialysepatienter                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Nyremedicinsk afdeling, Aalborg Sygehus</Primary_sponsor>
    <Date_registration3>20050824</Date_registration3>
    <Date_registration>24/08/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-002380-90                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>26/09/2005</Date_enrollement>
    <Target_size>70</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: yes&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: yes&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients with chronic renal failure undergoing haemodialysis treatment three times a week&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Allergy to fish or egg protein. Age &lt; 18 yrs. Body Weight &lt; 50 kg. Chronic supraventricular arrhythmias. Implanted pacemaker. Myocardial infarction or stroke within the past 6 months. Tendency to significant drop in bloodpressure during haemodialysis. Ongoing infection. Other serious illness. Fasting triglycerides &gt; 3 mmol/L. &lt;br&gt;</Exclusion_Criteria>
    <Condition>Chronic renal failure</Condition>
    <Intervention>&lt;br&gt;Trade Name: Omegaven&lt;br&gt;Product Name: Omegaven&lt;br&gt;Pharmaceutical Form: Emulsion for infusion&lt;br&gt;Pharmaceutical form of the placebo: Intravenous infusion&lt;br&gt;Route of administration of the placebo: Intravenous use&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To investigate the effect of intravenous infusion of an emulsion rich on n-3 polyunsaturated fatty acids on heart rate variability and the occurence of arrhythmias in relation to haemodialysis treatment;Secondary Objective: To determine the content of n-3 polyunsaturated fatty acids in plasma and cell membranes before and after infusion;Primary end point(s): The effect on heart rate variability and arrhythmias</Primary_outcome>
    <Secondary_ID>IVN3DIALYSE;N/A</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2454985</Internal_Number>
    <TrialID>EUCTR2004-005002-68-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Estudio multicéntrico, aleatorizado, doble ciego, paralelo y de fase IV para comparar los efectos en la función renal del medio de contraste no iónico, isosmolar, iodixanol 320 mgI/ml (VisipaqueTM) con el medio de contraste no iónico, de baja osmolalidad, iopamidol 370 mgI/ml, en sujetos con función renal disminuida y diabetes mellitus sometidos a una angiografía coronaria con o sin intervención coronaria percutánea (ICP).</Public_title>
    <Scientific_title>Estudio multicéntrico, aleatorizado, doble ciego, paralelo y de fase IV para comparar los efectos en la función renal del medio de contraste no iónico, isosmolar, iodixanol 320 mgI/ml (VisipaqueTM) con el medio de contraste no iónico, de baja osmolalidad, iopamidol 370 mgI/ml, en sujetos con función renal disminuida y diabetes mellitus sometidos a una angiografía coronaria con o sin intervención coronaria percutánea (ICP).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      </Scientific_title>
    <Primary_sponsor>Amersham Health SA (Parte de GE Healthcare Ltd. y sus filiales)</Primary_sponsor>
    <Date_registration3>20050922</Date_registration3>
    <Date_registration>22/09/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-005002-68                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>03/11/2005</Date_enrollement>
    <Target_size>450</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;(1) The subject is over 18 years of age. &lt;br&gt;(2) The subject is referred for coronary angiography with or without PCI.&lt;br&gt;(3) The subject has diabetes mellitus I or II, treated with insulin or oral antiglycemics for at least 1 year.&lt;br&gt;(4) The subject has renal impairment of non-acute aetiology:&lt;br&gt;SCr measurement not older than 6 months ?150 µmol/L (1.7 mg/dL) for men and  ?133 µmol/L (1.5 mg/dL) for women or a creatinine clearance = 50 mL/min calculated according to Cockcroft-Gault formula. &lt;br&gt;(5) The subject is able and willing to comply with study procedures including hydration protocol and signed and dated (i.e. date and time) informed consent is obtained.&lt;br&gt;(6) The subject is male, or a female who is either surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), postmenopausal (cessation of menses for more than 1 year), or non-lactating, or if of childbearing potential the results of a serum or urine human chorionic gonadotropin pregnancy test, performed at screening, with the result known before IMP administration, must be negative.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;(1) The subject was previously included in this study. &lt;br&gt;(2) The subject has participated in any IMP study within 30 days prior to study enrolment.&lt;br&gt;(3) The subject received iodinated contrast medium within 7 days before IMP administration or is scheduled to receive one within the study period.&lt;br&gt;(4) The subject is planned to undergo major surgery (CABG, CEA, vascular bypass) within 3 days after the IMP administration.&lt;br&gt;(5) The subject is planned to undergo selective renal angiography.&lt;br&gt;(6) The subject has a history of serious hypersensitivity reaction to iodinated contrast media.&lt;br&gt;(7) The subject has severe liver or haematologic disease, multiple myeloma or manifest thyrotoxicosis.&lt;br&gt;(8) The subject has severe heart failure requiring intravenous therapy with diuretics, inotropes, and/or vasodilators.&lt;br&gt;(9) The subject is planned to receive an intravenous diuretic or intravenous mannitol in connection to the IMP administration.&lt;br&gt;(10) The subject is haemodynamically unstable pre-study (i.e., inability to sustain systolic blood pressure above 90 mmHg within 48 hours before IMP-administration without pressor or balloon support).&lt;br&gt;(11) The subject is on haemodialysis or peritoneal dialysis, and/or is in acute renal failure. &lt;br&gt;(12) The subject has undergone kidney transplantation. &lt;br&gt;(13) The subject has received or will receive any of the following potentially nephroprotective drugs within 3 days before or 3 days after IMP administration; n-acetylcysteine, fenoldopam, dopamine or hydration with sodium bicarbonate (NaHCO3).  Potentially nephroprotective drugs such as Ca-channel blockers, theophylline etc, are allowed provided they are used for treatment of the subject’s chronic underlying disease. &lt;br&gt;(14) The subject has received or is planned to receive any of the following nephrotoxic drugs within 7 days before or 3 days after IMP administration; aminoglycosides, vancomycin, amphotericin B, cyclosporin, methotrexate, cisplatin.  &lt;br&gt;(15) The subject has received or is planned to receive nonsteroidal anti-inflammatory drugs (NSAID) within 3 days before or 3 days after IMP administration, with the exception of low dose acetyl salicylic acid (up to 325 mg per day, and at a single occasion in connection with PCI up to 500 mg).  However, subjects who are on a stable NSAID regimen may be enrolled.&lt;br&gt;(16) The subject has had or is planned to have the initiation, discontinuation, or change in dose within 3 days before or 3 days after IMP administration of any of the following: trimethoprim, cimetidine, angiotensin converting enzyme inhibitors (ACEI), or angiotensin receptor blockers (ARB).&lt;br&gt;(17) The subject is on metformin (e.g., Glucophage?) at the time of coronary angiography/intervention.  Metformin must be discontinued according to local guidelines, and stopped no later than the time of IMP administration, withheld for at least 48 hours, until the subject’s SCr has been evaluated and it is deemed safe to resume metformin.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Subjects with impaired renal function and diabetes mellitus undergoing coronary angiography.
 &lt;br&gt;MedDRA version: 8.0
Level: Pt
Classification code 10061835
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Visipaque 320 mg I/ml&lt;br&gt;Product Name: Visipaque&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Iodixanol&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 320 mg I/ml-&lt;br&gt;&lt;br&gt;Trade Name: Iopamiro 370 mg I/ml&lt;br&gt;Product Name: Iopamiro&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Iopamidol&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 370 mg I/ml-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To evaluate and compare the effects of two different contrast media, the iso-osmolar contrast medium (IOCM), iodixanol 320 mgI/mL, and the low-osmolar contrast medium (LOCM) iopamidol 370 mgI/mL, on renal function.;Secondary Objective: - To evaluate and compare the safety profile of iodixanol 320 mgI/mL and iopamidol 370 mgI/mL.&lt;br&gt;- To evaluate and compare the efficacy of iodixanol 320 mgI/mL and iopamidol 370 mgI/mL.&lt;br&gt;;Primary end point(s): - The peak increase in SCr from baseline up to day 3.&lt;br&gt;- The incidence of CIN, defined as number of subjects with an increase in SCr of at least 44.2 µmol/L (0.5 mg/dL) from baseline up to day 3.&lt;br&gt;</Primary_outcome>
    <Secondary_ID>DXV405</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2455044</Internal_Number>
    <TrialID>EUCTR2005-002372-16-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Multicenter, open-label, single-arm, safety, tolerability, efficacy and pharmacokinetic study of RAD001 in pediatric de novo renal transplant patients

Estudio multicéntrico, abierto, con un grupo de tratamiento, para evaluar la eficacia, la tolerabilidad, la seguridad y la farmacocinética de RAD001, en pacientes pediátricos receptores de un trasplante renal de novo - RAD351</Public_title>
    <Scientific_title>Multicenter, open-label, single-arm, safety, tolerability, efficacy and pharmacokinetic study of RAD001 in pediatric de novo renal transplant patients

Estudio multicéntrico, abierto, con un grupo de tratamiento, para evaluar la eficacia, la tolerabilidad, la seguridad y la farmacocinética de RAD001, en pacientes pediátricos receptores de un trasplante renal de novo - RAD351                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       </Scientific_title>
    <Primary_sponsor>Novartis Farmaceútica S.A</Primary_sponsor>
    <Date_registration3>20050906</Date_registration3>
    <Date_registration>06/09/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-002372-16                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>11/10/2005</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;a.Male and female patients ? 16 years of age.&lt;br&gt;b.Patients receiving a primary cadaveric or non-HLA identical living donor (related or unrelated) renal transplant.&lt;br&gt;c.The graft must be functional within 48 hours post transplantation. A functional graft is defined at the investigator’s determination by a 50 % fall of serum creatinine from the pre-transplant value. In the event of dialysis immediately preceding transplantation, the pre-dialysis serum creatinine value may be used.&lt;br&gt;d.Females capable of becoming pregnant must have a negative pregnancy test (qualitative dip stick test on urine) immediately prior to study entry. Females of child bearing potential must practice an approved method of birth control for the one year duration of the study and for a period of three months following discontinuation of study medication.&lt;br&gt;e.Patients who are willing and able to participate in the whole course of the study and for whom written informed consent has been obtained from the parent(s) or legal guardian.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? yes&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) no&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;a.Cold ischemia time &gt; 40 hours.&lt;br&gt;b.Patients who are recipients of multiple solid organ transplants, including dual and en bloc kidneys, or who have previously received transplanted organs.&lt;br&gt;c.Patients with non-diarrhea associated hemolytic-uremic syndrome.&lt;br&gt;d.Recipients of donor specific transfusions.&lt;br&gt;e.Patients with panel reactive T cell antibodies of 50 % or higher at the last assessment before transplantation.&lt;br&gt;f.Patients unable to undergo renal biopsies post-transplant. &lt;br&gt;g.Induction therapy with ALG, ATG and OKT3.&lt;br&gt;h.Use of anti-fungal azoles such as ketoconazole, itraconazole and fluconazole.&lt;br&gt;i.Patients requiring treatments with rifampin, carbamazepine, phenobarbital, phenytoin at the time of entry in the study.&lt;br&gt;j.The use of any investigational drug within 4 weeks prior to administration of the initial dose of study medication.&lt;br&gt;k.Patients who have received an investigational immunosuppressive agent within 4 months prior to administration of the initial dose of study medication.&lt;br&gt;l.Presence of any severe allergy (within 4 weeks prior to administration of the initial dose of study medication) requiring acute or chronic treatment; or hypersensitivity to drugs similar to RAD001 (e.g., erythromycin or other macrolide antibiotics) or to any component of the formulation.&lt;br&gt;m.Patients with any known contraindication to CsA.&lt;br&gt;n.Patients with severe or unstable medical conditions likely to affect patient safety or the objectives of this study. Other social circumstances that prevent full compliance with the protocol.&lt;br&gt;o.Patients with a history of alcohol or drug abuse, or signs of alcohol-induced organ damage, mental dysfunction or other factors limiting their ability to cooperate fully with the study.&lt;br&gt;p.Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of any drug. The investigator should be guided by evidence of any of the following:&lt;br&gt;presence of inflammatory bowel syndrome, or gastrointestinal bleeding;&lt;br&gt;history of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection (bladder augmentations and feeding tubes are acceptable).&lt;br&gt;q.Patients who are Hepatitis C positive, HIV positive, or Hepatitis B surface antigen positive. Laboratory results obtained within 6 months prior to administration of the initial dose of study medication are acceptable. Recipients of organs from donors who test positive for Hepatitis B surface antigen, Hepatitis C or HIV.&lt;br&gt;r.Evidence of liver injury as indicated by abnormal liver tests (AST or ALT &gt; 3 times ULN, total bilirubin &gt; 2 mg/dL).&lt;br&gt;s.Presence of uncontrolled hypercholesterolemia ( =350 mg/dL, = 9.1 mmol/L) or hypertriglyceridemia (= 500 mg/dL, = 5.6 mmol/L).&lt;br&gt;t.White blood cell count = 4500/mm3 or platelet count = 100,000/mm3.&lt;br&gt;u.Patients with severe systemic infections.&lt;br&gt;v.Patients with any past or present malignancy (other than excised basal cell carcinoma).&lt;br&gt;w.History of splenectomy.&lt;br&gt;x.Patients with any history of significant coagulopathy or medical condition requiring long term systemic anticoagulation after transplantation which would interfere with obtaining biopsies. Low dose aspirin is allowed.&lt;br&gt;y.Abnormal physical or laboratory findings of clinical significance which would interfere with the objectives of the study.&lt;br&gt;z.Females who are breast feeding.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>pediatric de novo renal trasplant &lt;br&gt;MedDRA version: 7.0
Level: LLT
Classification code 10050432
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Certican 0.1mg fast-dispersable tablets&lt;br&gt;Product Name: Certican&lt;br&gt;Product Code: RAD001B&lt;br&gt;Pharmaceutical Form: Dispersible tablet&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 1.5mg/day-&lt;br&gt;&lt;br&gt;Trade Name: Certican 0.25mg fast-dispersable tablets&lt;br&gt;Product Name: certican&lt;br&gt;Product Code: RAD001B&lt;br&gt;Pharmaceutical Form: Dispersible tablet&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: up to&lt;br&gt;Concentration number: 1.5mg/day-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: 1. To evaluate the safety and tolerability of RAD001 administered b.i.d. in combination with Neoral® and corticosteroids in pediatric de novo renal transplant recipients, and to provide additional safety data (quantitative protein/creatinine ratio in urine).;Primary end point(s): To evaluate the safety and tolerability of RAD001 administered b.i.d. in combination with Neoral® and corticosteroids in pediatric de novo renal transplant recipients;Secondary Objective: 1.To evaluate the efficacy of RAD001 administered b.i.d. in combination with Neoral® and corticosteroids as measured by the incidence of biopsy proven acute allograft rejection episodes, graft loss or death at 6 and 12 months after initial dose of study medication.&lt;br&gt;2.To characterize the multiple dose pharmacokinetics of RAD001 administered b.i.d.&lt;br&gt;3.To evaluate the efficacy of RAD001 administered b.i.d. in combination with Neoral® and corticosteroids in the prevention of chronic allograft rejection (chronic graft dysfunction) at 12 months post-transplantation.&lt;br&gt;</Primary_outcome>
    <Secondary_ID>CRAD001B351</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2455172</Internal_Number>
    <TrialID>EUCTR2005-001854-25-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Estudio comparativo de tacrolimus y rapamicina para evaluar la función renal en pacientes mayores de 50 años, receptores de un riñón de donante mayor de 55 años, en un régimen inmunosupresor de daclizumab y micofenolato mofetil. - ALHAMBRA</Public_title>
    <Scientific_title>Estudio comparativo de tacrolimus y rapamicina para evaluar la función renal en pacientes mayores de 50 años, receptores de un riñón de donante mayor de 55 años, en un régimen inmunosupresor de daclizumab y micofenolato mofetil. - ALHAMBRA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Sociedad Andaluza de Trasplante de Órganos y Tejidos</Primary_sponsor>
    <Date_registration3>20051010</Date_registration3>
    <Date_registration>10/10/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-001854-25                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>05/12/2005</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1. Pacientes de ambos sexos cuya edad sea mayor o igual a 50 años, y que sean receptores primarios de aloinjerto renal proveniente de donante mayor o igual a 55 años.&lt;br&gt;2. Pacientes que hayan otorgado su consentimiento de manera previa a su participación en el estudio.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Pacientes receptores de trasplante multiorgánico.&lt;br&gt;2. Pacientes que reciben trasplante de donante cadáver con un tiempo de isquemia fría mayos de 30 horas.&lt;br&gt;3. Pacientes con un PRA mayor del 20% en los 6 meses anteriores a la inclusión.&lt;br&gt;4. Mujeres en periodo de lactancia, embarazadas o en edad fértil, que no usen un método anticonceptivo fiable antes de comenzar la terapia con el fármaco en estudio, durante la terapia, y durante los 4 meses siguientes a la última dosis de los fármacos administrados dentro de este estudio clínico.&lt;br&gt;5. Pacientes con recuento leucocitario menor de 2,5 x 109/L, recuento de plaquetas menor de 100 x 109/L, o hemoglobina inferior a 6 g/dL en el momento de ser incluido en el estudio,&lt;br&gt;6. Pacientes con evidencia de enfermedad hepática activa.&lt;br&gt;7. Pacientes con úlcera péptica activa.&lt;br&gt;8. Pacientes con diarrea grave o cualquier otro trastorno intestinal que pudiera interferir en la capacidad de absorción de medicación oral, incluyendo pacientes diabéticos con gastroenteropatía diabética diagnosticada previamente,&lt;br&gt;9. Pacientes con evidencia de infección sistémica activa que requiera el uso continuado de antibióticos, o evidencia de infección por VIH, o presencia de hepatitis B (HBs-Ag positiva) o C crónica activa,&lt;br&gt;10. Pacientes con historia de malignidad (excepto cáncer de piel no melanocítico localizado, tratado satisfactoriamente y carcinoma “in situ” de cervix),&lt;br&gt;11. Pacientes con una historia de enfermedad, o afección psicológica, que interfiera en la capacidad del paciente para comprender los requisitos del estudio,&lt;br&gt;12. Pacientes en quienes el investigador considera necesario un tratamiento con la siguiente medicación: &lt;br&gt;a.	-Azatioprina,&lt;br&gt;b.	Metotrexato,&lt;br&gt;c.	Ciclofosfamida&lt;br&gt;d.	-Anticuerpos antilinfocitos policlonales y monoclonales (por ejemplo, OKT3, ATG), usados para la inducción en pacientes de alto riesgo inmunológico,&lt;br&gt;e.	Basiliximab,&lt;br&gt;f.	Otros fármacos en investigación,&lt;br&gt;&lt;br&gt;13. Hipersensibilidad conocida o contraindicación absoluta de cualquiera de las medicaciones administradas en el contexto del estudio, o cualquier otra sustancia presente en las medicaciones del  estudio.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Trasplante renal en pacientes mayores de 50 años, receptores de un riñón de donante mayor de 55 años.</Condition>
    <Intervention>&lt;br&gt;Trade Name: PROGRAF&lt;br&gt;Product Name: tacrolimus&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: tacrolimus&lt;br&gt;Concentration unit: mg/kg milligram(s)/kilogram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: RAPAMUNE&lt;br&gt;Product Name: SIROLIMUS&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: sirolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 10-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Comparar la función renal (creatinina sérica a los 6 meses) en la entrada tardía del tratamiento con tacrolimus o rapamicina basados en regímenes con daclizumab, micofenolato mofetil y esteroides en pacientes mayores de 50 receptores de un injerto de donante mayor de 55 años.;Secondary Objective: 1. Eficacia:&lt;br&gt;Comparar los datos relativos al retraso en la función del injerto.&lt;br&gt;Comparar los datos relativos al rechazo.&lt;br&gt;Comparar la supervivencia del paciente y del injerto tras 6 meses de tratamiento.&lt;br&gt;Comparar los datos relativos al fallo de tratamiento a los 6 meses.&lt;br&gt;2. Seguridad:&lt;br&gt;Describir la incidencia de acontecimientos adversos entre ambos brazos a lo largo de 6 meses de tratamiento.;Primary end point(s): creatinina sérica a los 6 meses</Primary_outcome>
    <Secondary_ID>SATOT42005</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2455280</Internal_Number>
    <TrialID>EUCTR2004-000520-32-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A MULTICENTRE, RANDOMISED, OPEN CLINICAL STUDY TO COMPARE THE EFFICACY AND SAFETY OF A COMBINATION OF TACROLIMUS AND MYCOPHENOLATE MOFETIL BASED REGIMEN WITH OR WITHOUT INDUCTION IN ELDERLY RECIPIENTS UNDERGOING KIDNEY TRANSPLANTATION
 - SENIOR (Safety and Efficacy with kNown Immunosuppression in Older Recipients)</Public_title>
    <Scientific_title>A MULTICENTRE, RANDOMISED, OPEN CLINICAL STUDY TO COMPARE THE EFFICACY AND SAFETY OF A COMBINATION OF TACROLIMUS AND MYCOPHENOLATE MOFETIL BASED REGIMEN WITH OR WITHOUT INDUCTION IN ELDERLY RECIPIENTS UNDERGOING KIDNEY TRANSPLANTATION
 - SENIOR (Safety and Efficacy with kNown Immunosuppression in Older Recipients)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>Fujisawa GmbH</Primary_sponsor>
    <Date_registration3>20051102</Date_registration3>
    <Date_registration>02/11/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000520-32                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>26/01/2005</Date_enrollement>
    <Target_size>230</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: different drug combination regimen&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1 Male or female patients minimum 60 years of age&lt;br&gt;2 Patient has end stage kidney disease and is a suitable candidate for primary renal transplantation or retransplantation&lt;br&gt;3. Patient is receiving a kidney transplant, from a cadaveric or living donor (not HLA identical) with compatible ABO blood type&lt;br&gt;4. Patient has been fully informed and has given written informed consent according to ICH-GCP. Patient unable to write and/or read but who fully understands the oral information given by the investigator (or nominated representative) has given oral informed consent witnessed by an independent person&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1. Patient has an immunological high risk, defined as a PRA grade &gt;50% &lt;br&gt;2. Cold ischemia time of the donor kidney greater than 30 hours&lt;br&gt;3. Patient has significant liver disease, defined as having during the past 30 days continuously elevated ASAT (SGOT) and/or ALAT (SGPT) levels greater than 2 times the upper value of the normal range of the investigational site or is receiving a graft from a hepatitis C or B positive donor&lt;br&gt;4. Patient is allergic or intolerant to corticosteroids, macrolide antibiotics, mycophenolate mofetil, mycophenolic acid, tacrolimus, basiliximab or to the excipients of the study medication&lt;br&gt;5. Patient requires ongoing dosing with corticosteroids &lt;br&gt;6. Patient requires initial sequential or parallel therapy with immunosuppressive antibody preparation(s) or prohibited medication (see section 7.4 of protocol)&lt;br&gt;7. Patient or donor is known to be HIV positive&lt;br&gt;8. Patient with malignancy or history of malignancy, except non-metastatic basal or squamous cell carcinoma of the skin that has been treated successfully&lt;br&gt;9. Patient has significant, uncontrolled concomitant infections and/or severe diarrhoea, vomiting, active upper gastro-intestinal tract malabsorption or active peptic ulcer&lt;br&gt;10. Patient is participating or has participated in another clinical trial and/or is taking or has been taking an investigational drug in the past 30 days&lt;br&gt;11. Patient has previously received or is receiving an organ transplant other than kidney&lt;br&gt;12. Patient has been previously enrolled in this study&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Patients with end stage kidney disease who will undergo primary renal transplantion or retransplantation &lt;br&gt;MedDRA version: 7.0
Level: LLT
Classification code 10014646
</Condition>
    <Intervention>&lt;br&gt;Trade Name: Prograf&lt;br&gt;Product Name: Prograf&lt;br&gt;Product Code: FK506&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: Tacrolimus&lt;br&gt;CAS Number: 109581-93-3&lt;br&gt;Current Sponsor code: FK506&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.5-&lt;br&gt;&lt;br&gt;Trade Name: Prograf&lt;br&gt;Product Name: Prograf&lt;br&gt;Product Code: FK506&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: Tacrolimus&lt;br&gt;CAS Number: 109581-93-3&lt;br&gt;Current Sponsor code: FK506&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1.0-&lt;br&gt;&lt;br&gt;Trade Name: Prograf&lt;br&gt;Product Name: Prograf&lt;br&gt;Product Code: FK506&lt;br&gt;Pharmaceutical Form: Capsule, hard&lt;br&gt;INN or Proposed INN: Tacrolimus&lt;br&gt;CAS Number: 109581-93-3&lt;br&gt;Current Sponsor code: FK506&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5.0-&lt;br&gt;&lt;br&gt;Trade Name: CellCept&lt;br&gt;Product Name: CellCept&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: Mycophenolate mofetil&lt;br&gt;CAS Number: 116680-01-4&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 250-&lt;br&gt;&lt;br&gt;Trade Name: Simulect&lt;br&gt;&lt;br&gt;Product Name: Simulect&lt;br&gt;Pharmaceutical Form: Powder for solution for injection&lt;br&gt;INN or Proposed INN: Basiliximab  &lt;br&gt;CAS Number: 179045-86-4&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 20.00-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To compare renal function as well as incidence of renal dysfunction, patient death, graft loss or first biopsy proven acute rejection within the first 6 months after transplantation for the two therapy regimens (Arm 1: Delayed Tacrolimus + MMF+ Basiliximab + Corticosteroids (1 week), Arm 2: Tacrolimus + MMF + Corticosteroids (3 months)). The aim is to demonstrate that Arm 1 is non-inferior to Arm 2 with regard to the primary endpoint.;Secondary Objective: To compare the efficacy and safety profiles of the two therapy regimens (Arm 1: Delayed Tacrolimus + MMF+ Basiliximab + Corticosteroids (1 week), Arm 2: Tacrolimus + MMF + Corticosteroids (3 months)). &lt;br&gt;;Primary end point(s): A two step testing strategy will be applied for the two primary endpoints. The first primary efficacy endpoint of this study will be the renal function measured by calculated creatinine clearance at month 6, determined from the serum creatine using the Cockcroft formula.&lt;br&gt;&lt;br&gt;If the result of the test for the first primary endpoint is statistically significant, then the composite endpoint can also be tested in a confirmatory way.&lt;br&gt;&lt;br&gt;The composite endpoint is the incidence of death, graft loss or acute rejection within the first 6 months after transplantation and incidence of renal dysfunction defined as a calculated creatinine clearance value of =40 ml/min/1.73 m2 at month 6. &lt;br&gt;</Primary_outcome>
    <Secondary_ID>FG-506-02-42</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2455320</Internal_Number>
    <TrialID>EUCTR2004-001270-77-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Estudio piloto para evaluar la eficacia y seguridad de Valsartán para el control de la progresión de la insuficiencia renal y la morbimortalidad cardiovascular en pacientes con trasplante renal funcionante con proteinuria e insuficiencia renal leve o moderada.</Public_title>
    <Scientific_title>Estudio piloto para evaluar la eficacia y seguridad de Valsartán para el control de la progresión de la insuficiencia renal y la morbimortalidad cardiovascular en pacientes con trasplante renal funcionante con proteinuria e insuficiencia renal leve o moderada.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            </Scientific_title>
    <Primary_sponsor>Equipo de doctores: Dr. Amado Andrés y Dr. Manuel Praga</Primary_sponsor>
    <Date_registration3>20051103</Date_registration3>
    <Date_registration>03/11/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-001270-77                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>01/03/2005</Date_enrollement>
    <Target_size>178</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: yes&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;1.	Hombres y mujeres con edad entre 18 y 70 años de edad, con un trasplante renal funcionante de más de 1 año, sea cual sea la causa de la insuficiencia renal terminal que lo haya motivado (nefropatía diabética o no diabética)&lt;br&gt;2.	Insuficiencia renal leve o moderada, definida como una creatinina sérica &gt; 1,3 mg/dl en las mujeres y &gt; 1,5 mg/dl en los  varones y &lt; 3 mg/dl en ambos casos. &lt;br&gt;3.	Proteinuria &gt; 0,5 g/24 h en al menos 3 determinaciones previas al inicio del estudio y &lt; 3, 5 g /24 h.&lt;br&gt;4.	En el momento de la aleatorización y durante las 6 semanas previas a la misma, los pacientes no estarán tomando IECA o ARAII como tratamiento antihipertensivo.&lt;br&gt;5.	Se incluirá a los pacientes con estos criterios independientemente de su presión arterial, es decir, podrán ser incluidos tanto pacientes normotensos como hipertensos. No obstante, la presencia de una hipertensión de difícil control constituirá un criterio de  exclusión.&lt;br&gt;6.	No será requisito necesario la realización de biopsia renal antes del inicio del estudio. Si se hubiera realizado, los pacientes podrán ser incluidos independientemente del diagnóstico establecido (rechazo crónico, glomerulonefritis de novo o de recidiva...) siempre que cumplan los criterios de inclusión/exclusión.&lt;br&gt;&lt;br&gt;&lt;br&gt;7.	La inmunosupresión empleada en estos pacientes estará basada en Ciclosporina A y los pacientes no deben estar incluidos en ningún otro protocolo de estudio en el momento de su reclutamiento.&lt;br&gt;8.	Las mujeres potencialmente fértiles deberán presentar una prueba de embarazo negativa antes de la aleatorización y deberán practicar un método anticonceptivo probado médicamente durante todo el ensayo. &lt;br&gt;9.	El paciente ha de otorgar su consentimiento informado por escrito para participar en el estudio.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;1.	Diagnóstico de más de 2 episodios de rechazo agudo hasta el inicio del estudio.&lt;br&gt;2.	Presencia de uropatía obstructiva no resuelta.&lt;br&gt;3.	Presencia de estenosis de arteria renal del injerto no resuelta&lt;br&gt;4.	Hepatopatía severa&lt;br&gt;5.	Enfermedad sistémica o deterioro general que haga previsible la imposibilidad de su seguimiento regular.&lt;br&gt;6.	Embarazo o lactancia&lt;br&gt;7.	Alteraciones psiquiátricas&lt;br&gt;8.	Hipersensibilidad conocida a los antagonistas de receptores de angiotensina (ARAII)&lt;br&gt;9.	Potasio sérico superior a 5.5 mEq/l en ausencia de fármacos que lo justifiquen.  &lt;br&gt;10.	Creatinina sérica &gt; 3.0 mg/dl o proteinuria &gt; 3,5 g/24h.&lt;br&gt;11.	Pacientes que hayan utilizado cualquier fármaco en investigación en las 6 semanas previas.&lt;br&gt;12.	Antecedentes de abuso de alcohol o de drogas no resuelto.&lt;br&gt;13.	Pacientes receptores de trasplantes de múltiples órganos sólidos o trasplantados previamente con cualquier otro órgano.&lt;br&gt;14.	Pacientes con alguna enfermedad maligna durante los últimos 5 años, excepto carcinoma de células basales o escamosas extirpado o carcinoma de cérvix in situ tratado adecuadamente.&lt;br&gt;15.	Estar participando en el momento de inclusión en otros protocolos de estudio.&lt;br&gt;16.	Hipertensión arterial de difícil control.&lt;br&gt;&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Pacientes varones y mujeres de 18 a 70 años con trasplantes renales funcionantes de más de 1 año de evolución y una insuficiencia renal leve o moderada (creatinina sérica &gt; 1,3 mg/dl en mujeres y &gt; 1,5 mg/dl en varones y &lt; 3 mg/dl en ambos casos) y proteinuria (&gt;0,5 g/24 h y &lt; 3,5 g/24 h).</Condition>
    <Intervention>&lt;br&gt;Trade Name: DIOVAN&lt;br&gt;Product Name: Diovan&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: VALSARTÁN&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 80-160&lt;br&gt;&lt;br&gt;Product Name: HIPOTENSORES&lt;br&gt;Product Code: C02&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;Product Name: DIURETICOS&lt;br&gt;Product Code: C03&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;Product Name: VASODILATADORES PERIFÉRICOS&lt;br&gt;Product Code: C04&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;Product Name: BETABLOQUEANTES&lt;br&gt;Product Code: C07&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;Product Name: CALCIO ANTAGONISTAS&lt;br&gt;Product Code: C08&lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Evaluar la eficacia de Valsartán en comparación con el tratamiento estándar para el control de la progresión de la insuficiencia renal, definida como un incremento de la creatinina sérica igual o superior al 50% del valor basal, en pacientes con trasplantes renales funcionantes con proteinuria e insuficiencia renal leve o moderada.;Secondary Objective: 1.	La reducción de la proteinuria&lt;br&gt;2.	Tolerabilidad de valsartán, evaluada mediante la frecuencia, tipo y gravedad de los acontecimientos adversos observados durante el estudio.  Se valorará la seguridad mediante exploraciones físicas, parámetros de laboratorio hematológicos y bioquímicos (incluyendo la determinación de creatinina y potasio) y medición de las constantes vitales.&lt;br&gt;3.	La morbimortalidad cardiovascular, evaluada mediante la incidencia global y específica de cada uno de los siguientes parámetros:&lt;br&gt;-	infarto agudo de miocardio o angina de pecho&lt;br&gt;-	necesidad de revascularización coronaria&lt;br&gt;-	episodios de insuficiencia cardiaca&lt;br&gt;-	accidente vascular cerebral&lt;br&gt;-	amputación y/o revascularización de extremidades inferiores&lt;br&gt;-	muerte de causa cardiovascular&lt;br&gt;;Primary end point(s): Porcentaje de pacientes con progresión de la insuficiencia renal, definida como un incremento de la creatinina sérica igual o superior al 50% del valor basal.	&lt;br&gt;</Primary_outcome>
    <Secondary_ID>TRASVAL</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2455462</Internal_Number>
    <TrialID>EUCTR2004-000655-41-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A one-year, multicenter, open-label, feasibility study to evaluate the safety and the efficacy of FTY720 5mg introduction and CNI elimination in adult maintenance renal transplant reicpients maintained on a triple immunosuppressive regimen with either MPA or mTOR inhibitor</Public_title>
    <Scientific_title>A one-year, multicenter, open-label, feasibility study to evaluate the safety and the efficacy of FTY720 5mg introduction and CNI elimination in adult maintenance renal transplant reicpients maintained on a triple immunosuppressive regimen with either MPA or mTOR inhibitor                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               </Scientific_title>
    <Primary_sponsor>Novartis Farmacéutica S.A</Primary_sponsor>
    <Date_registration3>20051201</Date_registration3>
    <Date_registration>01/12/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2004-000655-41                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>10/02/2005</Date_enrollement>
    <Target_size>88</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: &lt;br&gt;Placebo: &lt;br&gt;Other: &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;male and female adults between 6 and 60 months post renal transplantation, maintained for the last 6 months on the same triple immunussupressive regimen : CNI + MPA + corticosteroids or CNI + mTOR + corticosteroids&lt;br&gt;stable renal function and no history of rejection&lt;br&gt;PRA &lt;10% pre-transplantation&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;patient at high immunological risk of rejection&lt;br&gt;pulse rate &lt; 50bpm at screening&lt;br&gt;presence or history of second or third degree AV block&lt;br&gt;history of cardiac arrest&lt;br&gt;history of malignancy&lt;br&gt;systemic infection within 2 weeks prior to start study medication&lt;br&gt;HIV or hepatitis B surface Ag positive&lt;br&gt;</Exclusion_Criteria>
    <Condition>prevention of acute rejection in maintenance renal transplant recipients &lt;br&gt;MedDRA version: 7.0
Level: LLT
Classification code 10023439
</Condition>
    <Intervention>&lt;br&gt;Product Name: FTY720&lt;br&gt;Product Code: FTY720&lt;br&gt;Pharmaceutical Form: Capsule*&lt;br&gt;INN or Proposed INN: Not applicable&lt;br&gt;Current Sponsor code: FTY720&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 2.5-5&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Evaluate whether FTY720 can be safely introduced in a maintenance renal transplant population and can allow for CNI elimination resulting in an improvement of the renal function ;Secondary Objective: Validate discharge criteria following the first administration of FTY720;Primary end point(s): improvement of the renal function 12 months after FTY720 introduction, measured by the change in estimated glomerular filtration rate (Cockroft-Gault formula)</Primary_outcome>
    <Secondary_ID>CFTY720A2308</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2455483</Internal_Number>
    <TrialID>EUCTR2005-004299-19-CZ</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>New Possibilities of TDM of Cyclosporine A and its metabolites after kidney transplantation</Public_title>
    <Scientific_title>New Possibilities of TDM of Cyclosporine A and its metabolites after kidney transplantation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     </Scientific_title>
    <Primary_sponsor>University Hospital Ostrava</Primary_sponsor>
    <Date_registration3>20051007</Date_registration3>
    <Date_registration>07/10/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-004299-19                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>26/10/2005</Date_enrollement>
    <Target_size>375</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: no&lt;br&gt;Open: yes&lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;renal transplant patients on standart therapy with cyclosporine A&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;end of treatment with cyclosporine A, disagreement of patients&lt;br&gt;</Exclusion_Criteria>
    <Condition>patient on standart immunusupresive therapy with cyclosporine A after renal transplantation</Condition>
    <Intervention>&lt;br&gt;Trade Name: not fixed in the protocol&lt;br&gt;Pharmaceutical Form: &lt;br&gt;INN or Proposed INN: CICLOSPORINUM&lt;br&gt;CAS Number: 59865-13-3&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: The target of this project is to clarify the importance of TDM of CsA and its principal metabolites by LC-MS in lymphocytes when compared with currently used methods C through, AUC, and C2. ;Secondary Objective: We further wish for detection the role of the lipofile metabolite AM4N in imunosupresion and toxicity, and alternatively other metabolites analyzed by LC-MS.;Primary end point(s): to clarify the importance of TDM of CsA and its principal metabolites by LC-MS in lymphocytes when compared with currently used methods C through, AUC, and C2. We further wish for detection the role of the lipofile metabolite AM4N in imunosupresion and toxicity, and alternatively other metabolites analyzed by LC-MS.&lt;br&gt;to find the therapeutic range for safety and effective therapy with CsA</Primary_outcome>
    <Secondary_ID>1A/8655-5</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2455503</Internal_Number>
    <TrialID>EUCTR2005-003383-39-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A randomized, open-label, multi-center study comparing a steroid sparing regimen versus standard steroid regimen in combination with daclizumab, mycophenolate mofetil and sirolimus in the prevention of acute renal allograft rejection.Estudio abierto, aleatorizado, multicéntrico, nacional, comparando un régimen libre de esteroides frente a un régimen de esteroides estándar, en combinación con Daclizumab, Micofenolato Mofetil y Sirolimus, en la prevención del rechazo agudo en trasplante renal.</Public_title>
    <Scientific_title>A randomized, open-label, multi-center study comparing a steroid sparing regimen versus standard steroid regimen in combination with daclizumab, mycophenolate mofetil and sirolimus in the prevention of acute renal allograft rejection.Estudio abierto, aleatorizado, multicéntrico, nacional, comparando un régimen libre de esteroides frente a un régimen de esteroides estándar, en combinación con Daclizumab, Micofenolato Mofetil y Sirolimus, en la prevención del rechazo agudo en trasplante renal.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Roche Farma S.A.</Primary_sponsor>
    <Date_registration3>20051111</Date_registration3>
    <Date_registration>11/11/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-003383-39                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>29/12/2005</Date_enrollement>
    <Target_size />
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;–	Patients who are males or non-pregnant females &gt; 18 years old.&lt;br&gt;–	Patients who are recipients of primary kidney allografts.&lt;br&gt;–	Patients who are single-organ recipients (kidney only).&lt;br&gt;–	Patients with PRA &lt;20%&lt;br&gt;–	If patients are women of childbearing potential, they must have a negative pregnancy test, and use a reliable form of contraception&lt;br&gt;–	Patients and their guardians must be capable of understanding the purpose and risks of the study.&lt;br&gt;–	Patients who are willing to give written informed consent.&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;–	Patients previously treated with Daclizumab, MMF or SRL.&lt;br&gt;–	Patients who require in addition to the study immunosuppresive regimen anti-lymphocyte preparations for induction therapy.&lt;br&gt;–	Women lactating, pregnant or of childbearing potential not using a reliable contraceptive method during the study.&lt;br&gt;–		Patients with severe gastrointestinal disorders that interfere with  &lt;br&gt;Their ability to receive or absorb oral medication and patients with severe diarrhoea.&lt;br&gt;–	Patients who are expected than to require oral corticosteroids post-transplant (i.e. patients suffering autoinmune diseases).&lt;br&gt;–	Patients with active peptic ulcer disease.&lt;br&gt;–	Patients receiving bile-acid sequestrants.&lt;br&gt;–	Patients with severe anemia (Hb&lt;6 g/dl), leucopenia (WBC&lt;2500/mm3) or thrombocytopenia (Tc&lt;100’000/mm3)&lt;br&gt;–	Patients with a history of a psychological illness or condition such as to interfere with the patient's ability to understand the requirements of the study.&lt;br&gt;–	HIV positive donor or patient&lt;br&gt;–	Patients with history of malignancy within the last 5 years, except localised and treated non melanoma skin cancer, treated and without recidive evidence.	&lt;br&gt;–	Patients for whom the investigator considers a treatment with the following medications necessary:&lt;br&gt;?	Azathioprine,&lt;br&gt;?	methotrexate&lt;br&gt;?	cyclophosphamide,&lt;br&gt;?	Cyclosporine&lt;br&gt;?	Tacrolimus&lt;br&gt;?	Everolimus&lt;br&gt;?	Mycophenolate sodium&lt;br&gt;?	polyclonal and monoclonal anti-lymphocyte antibodies other than daclizumab (e.g. OKT3, ATG, basiliximab) &lt;br&gt;–	Known hypersensitivity or absolute contraindications to any of the medications administered in the context of the study or any other substances present in the study medications&lt;br&gt;–		Patients who require concomitant treatment with other investigational or prohibited drugs.&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal Transplant</Condition>
    <Intervention>&lt;br&gt;Trade Name: Rapamune&lt;br&gt;Product Name: Rapamune&lt;br&gt;Pharmaceutical Form: Coated tablet&lt;br&gt;INN or Proposed INN: Sirolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: Rapamune&lt;br&gt;Product Name: Rapamune&lt;br&gt;Pharmaceutical Form: Oral solution&lt;br&gt;INN or Proposed INN: sirolimus&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: ZENAPAX&lt;br&gt;Product Name: Daclizumab&lt;br&gt;Pharmaceutical Form: Solution for infusion&lt;br&gt;INN or Proposed INN: Daclizumab&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 5-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To compare the efficacy of a steroid free regimen against normal doses of corticosteroids for prevention of acute rejection, when given in conjunction with daclizumab, mycophenolate mofetil (MMF) and sirolimus as maintenance therapy in the management of renal allograft recipients.;Secondary Objective: To assess clinical efficacy and safety of  the two treatment regimens&lt;br&gt;;Primary end point(s): Proportion of patients experiencing a biopsy proven acute rejection episode 6 months post-randomization</Primary_outcome>
    <Secondary_ID>ML18690</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2455613</Internal_Number>
    <TrialID>EUCTR2005-004431-21-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Estudio abierto, multicéntrico, aleatorio, con el objetivo de evaluar la eficacia y la seguridad de la inmunosupresión tras un primer trasplante renal cadavérico a corazón latiente basado la utilización de suero anti-linfocitos T de conejo, tacrolimus y micofenolato, libre de corticoesteroides concomitantes desde el inicio. - IBERICA</Public_title>
    <Scientific_title>Estudio abierto, multicéntrico, aleatorio, con el objetivo de evaluar la eficacia y la seguridad de la inmunosupresión tras un primer trasplante renal cadavérico a corazón latiente basado la utilización de suero anti-linfocitos T de conejo, tacrolimus y micofenolato, libre de corticoesteroides concomitantes desde el inicio. - IBERICA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Fresenius Biotech GmbH</Primary_sponsor>
    <Date_registration3>20051219</Date_registration3>
    <Date_registration>19/12/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-004431-21                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>17/02/2006</Date_enrollement>
    <Target_size>160</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: yes&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: Triple terapia Tacro/MMF/Corticosteroides&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Varón o mujer adulto, candidato para un primer transplante cadavérico, hasta los 70 años.&lt;br&gt;Las mujeres que se encuentren en edad fértil deberán utilizar métodos anticonceptivos seguros a lo largo de todo el estudio.&lt;br&gt;Donante a corazón latiente hasta los 65 años de edad, con de isquemia fría &lt;36 horas.&lt;br&gt;El paciente que haya recibido la información relativa al estudio y prestado su consentimiento informado por escrito.&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Embarazo actual o en período de lactancia. &lt;br&gt;Mujeres que hayan tenido más de 3 embarazos (incluidos abortos). &lt;br&gt;Paciente con riesgo inmunológico considerado alto, definido por la presencia de un porcentaje de anticuerpos anti-HLA (PRA) ³25 %.&lt;br&gt;Hipersensibilidad a las proteínas del conejo (¿test cutáneo?) o alergias conocidas a cualquier componente de la inmunosupresión prevista. &lt;br&gt;Paciente/Donante HCV+, HBV+, HIV+&lt;br&gt;Paciente en tratamiento inmunosupresor pretransplante.&lt;br&gt;Paciente con neoplasia maligna actual o con antecedentes de neoplasia maligna, a excepción de cánceres basocelulares o espinocelulares en remisión. &lt;br&gt;Paciente sometido algún tipo de trasplante previo o candidato a trasplante múltiple (p.ej SKP).&lt;br&gt;Leucocitos &lt;2000/mm3 y/o plaquetas &lt;50 000/mm3 antes de iniciar el trasplante&lt;br&gt;</Exclusion_Criteria>
    <Condition>Trasplante renal de donante cadavérico</Condition>
    <Intervention>&lt;br&gt;Trade Name: ATeGe Fresenius&lt;br&gt;Product Name: ATeGe-Fresenius&lt;br&gt;Product Code: ATG&lt;br&gt;Pharmaceutical Form: Concentrate for solution for injection&lt;br&gt;INN or Proposed INN: Inmunoglobulina de conejo anti-linfocitos T humanos&lt;br&gt;Other descriptive name: ATG Fresenius&lt;br&gt;Concentration unit: mg/ml milligram(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 100-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: Incidencia de rechazo subclínico y rechazo agudo (demostrados por biopsia).&lt;br&gt;   incidencia y lapso de tiempo hasta su manifestación&lt;br&gt;   gravedad histológica (BANFF)&lt;br&gt;   incidencia de resistencia a los corticoesteroides;Secondary Objective: Incidencia y duración de retraso inicial función injerto.&lt;br&gt;Función renal a los 1, 3, 6, 12 meses.&lt;br&gt;Porcentaje de pacientes proteinúricos y cantidad de proteína secretada&lt;br&gt;Porcentaje de pacientes con hipertensión arterial y en tratamiento hipotensor.&lt;br&gt;Porcentaje de pacientes hiperlipidémicos y en tratamiento hipolipemiante&lt;br&gt;Porcentaje de diabetes mellitas post-trasplante&lt;br&gt;Fallo de tratamiento y porcentaje de pacientes libres de esteroides al año.&lt;br&gt;Incidencia de complicaciones infecciosas bacterianas, víricas, fúngicas o parasitarias al año.  &lt;br&gt;Incidencia de neoplasias y enfermedad linfoproliferativa post-trasplante al año&lt;br&gt;Incidencia de cataratas&lt;br&gt;Incidencia de fracturas y osteoporosis diagnosticada densitometría osea al año&lt;br&gt;Incidencia de complicaciones cardiovasculares al año&lt;br&gt;Supervivencia total de pacientes al año&lt;br&gt;Supervivencia del injerto al año&lt;br&gt;Histología renal al año ;Primary end point(s): Evaluación de eficacia: La eficacia será valorada por la observación de eventos de rechazo agudo y rechazo agudo subclínico.&lt;br&gt;Evaluación de seguridad/tolerancia:La seguridad y tolerancia será determinada por la observación de graves efectos adversos. La evaluación incluirá pruebas clínicas y de laboratorio (exploración física, constantes vitales, hematología, bioquímica  y análisis de orina).</Primary_outcome>
    <Secondary_ID>IBERICA</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2455627</Internal_Number>
    <TrialID>EUCTR2005-005664-88-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Prospective Study of Mycobacterium Tuberculosis Specific Cellular immune Responses in Iatrogenically Immunosuppressed Patients: those undergoing TNF-alpha blockade or Awaiting Renal Trasnplants: A Potential New Method For Accurate Diagnosis of Latent Tuberculosis Infection in Clinical Practice - Diagnosis of Latent TB Infection in Anti-TNF alpha or Dialysis</Public_title>
    <Scientific_title>Prospective Study of Mycobacterium Tuberculosis Specific Cellular immune Responses in Iatrogenically Immunosuppressed Patients: those undergoing TNF-alpha blockade or Awaiting Renal Trasnplants: A Potential New Method For Accurate Diagnosis of Latent Tuberculosis Infection in Clinical Practice - Diagnosis of Latent TB Infection in Anti-TNF alpha or Dialysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         </Scientific_title>
    <Primary_sponsor>University of Oxford</Primary_sponsor>
    <Date_registration3>20051215</Date_registration3>
    <Date_registration>15/12/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005664-88                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>08/12/2006</Date_enrollement>
    <Target_size>520</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: &lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: The RD1 based ex vivo enzyme linked immunospot assay&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Patients in chronic renal failure who are potential transplant recipients &lt;br&gt;OR &lt;br&gt;Patients with a rheumatological condition who are potential recipients of Tumour Necrosis Factor alpha blockade&lt;br&gt;&lt;br&gt;AND &lt;br&gt;adult (over 18)&lt;br&gt;AND&lt;br&gt;able to give written informed consent&lt;br&gt;AND &lt;br&gt;with risk factors for tuberculosis:&lt;br&gt;-[renal arm] from collaborating units in high prevalence areas of the UK&lt;br&gt;-[anti TNF alpha arm] patients who would be considered for tuberculin skin testing under current anti-TNFalpha treatment guidelines, including past history of exposure or disease, immigrant from high prevalence area, CXR changes suggestive of prior TB, grade 2 heaf test or above&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Children&lt;br&gt;Current active tuberculosis&lt;br&gt;Unable to give written informed consent&lt;br&gt;Hypersensitivity to tuberculin&lt;br&gt;</Exclusion_Criteria>
    <Condition>Renal failure and iatrogenic immunosuppression associated with solid organ transplantation or TNF alpha blockade in rheumatoid arthritis
ICD 10 codes included: N18 Z94.0 M05 M06 M07 M45</Condition>
    <Intervention>&lt;br&gt;Trade Name: Tuberculin PPD RT 23 SSI for mantoux testing&lt;br&gt;Product Name: Tuberculin PPD RT 23 SSI for mantoux testing&lt;br&gt;Product Code: 1&lt;br&gt;Pharmaceutical Form: Injection*&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To validate the use of the RD1 based Exvivo IFNy ELISpot in the immunodiagnosis of tuberculosis in iatrogenically immunosuppressed populations by calculation of positive and negative predictive values for the assay and for a comparator: the tuberculin based mantoux test;Secondary Objective: To investigate potential immune correlates of latency and active disease in tuberculosis and identify potential markers of prognosis and disease progression in tuberculosis.;Primary end point(s): Development of active tuberculosis</Primary_outcome>
    <Secondary_ID>HB996</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2455632</Internal_Number>
    <TrialID>EUCTR2005-001714-41-ES</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Estudio multicéntrico, abierto, randomizado,  de doce meses de duración,  sobre la seguridad, tolerabilidad y eficacia de Certican®, administrado junto a un antagonista del receptor IL-2, corticoesteroides y dos niveles de exposición diferentes de tacrolimus, en pacientes con trasplante renal de novo

</Public_title>
    <Scientific_title>Estudio multicéntrico, abierto, randomizado,  de doce meses de duración,  sobre la seguridad, tolerabilidad y eficacia de Certican®, administrado junto a un antagonista del receptor IL-2, corticoesteroides y dos niveles de exposición diferentes de tacrolimus, en pacientes con trasplante renal de novo

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 </Scientific_title>
    <Primary_sponsor>Novartis Farmacéutica, S.A.</Primary_sponsor>
    <Date_registration3>20051205</Date_registration3>
    <Date_registration>05/12/2005</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-001714-41                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>24/05/2006</Date_enrollement>
    <Target_size>230</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: no&lt;br&gt;Double blind: no&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;El investigador debe asegurarse de que cada paciente cumple todos los criterios de inclusión al momento de ingresar en el estudio (basal), inmediatamente antes de la aleatorización: &lt;br&gt;- Hombre o mujeres entre 18 y 65 años de edad.&lt;br&gt;- Paciente que haya recibido un primer trasplante de riñón de un donante cadavérico, de un donante vivo no emparentado o de un donante vivo emparentado con HLA no idéntico.&lt;br&gt;- Receptor de un riñón con un tiempo de isquemia fría (TIF) &lt; 30 horas.&lt;br&gt;- Receptor de un riñón procedente de un donante que tiene entre 10 y 65 años de edad.&lt;br&gt;- Paciente capaz de recibir la primera dosis de tacrolimus dentro de las 24 horas de efectuada la reperfusión del injerto.&lt;br&gt;- Mujeres con capacidad de procrear deben tener una prueba de embarazo negativa, y es necesario que utilicen un método anticonceptivo médicamente probado durante el estudio y por un periodo de tres meses tras la discontinuación del fármaco en investigación.&lt;br&gt;- Paciente dispuesto y capaz de dar consentimiento informado escrito para participar en el estudio y capaz de participar en el estudio durante 12 meses.&lt;br&gt;&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) no&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;El paciente que cumpla con alguno de los siguientes criterios al momento de ingresar al estudio (basal) justo antes de la aleatorización no podrá participar en el estudio:&lt;br&gt;- Paciente que anteriormente haya recibido un trasplante de órgano.&lt;br&gt;- Receptor de trasplante múltiple de órganos.&lt;br&gt;- Receptor de un trasplante de riñón de un donante a corazón parado .&lt;br&gt;- Receptor con transfusiones específicas del  donante&lt;br&gt;- Receptor de un trasplante A-B-O incompatible o trasplante con cross-match para células T positivo.&lt;br&gt;- Paciente con un nivel actual con Panel de Anticuerpos Reactivos (PRA) = 50%.&lt;br&gt;- Receptor de un riñón de un donante con  antígeno de superficie positivo de la hepatitis B o anticuerpos contra hepatitis C .&lt;br&gt;- Paciente positivo para el virus de inmunodeficiencia humano (HIV).&lt;br&gt;- Paciente con serología positiva para hepatitis C, o que es positivo para el antígeno de superficie de la hepatitis B con evidencia de daño hepático indicado por niveles de AST/ALT = 2.5 veces el LSN. Se aceptan los resultados de serología viral obtenidos dentro de los 6 meses previos a la administración de la primera dosis de Certican®.&lt;br&gt;- Paciente con hipercolesterolemia severa ( = 350 mg/dl, 9.1 mmol/dl) o hipertrigliceridemia severa     ( = 500 mg/dl, 5.6 mmol/l).&lt;br&gt;- Paciente con recuento de glóbulos blancos (WBC) &lt; o = 3.000/mm3 o recuento plaquetario &lt; o =  75,000/mm3&lt;br&gt;- Paciente con alguna alergia severa que requiere tratamiento agudo (dentro de las 4 semanas anteriores al examen basal) o crónico, o que presenta hipersensibilidad a fármacos similares a Certican® (Ej. macrólidos).&lt;br&gt;- Paciente que ha recibido tratamiento con un fármaco inmunosupresor o un fármaco en investigación dentro de las 4 semanas previas a la administración de la primera dosis de Certican®.&lt;br&gt;- Paciente con infección no controlada.&lt;br&gt;- Paciente con alguna condición médica o quirúrgica, distinta del actual trasplante, que a criterio del investigador impida la participación en este ensayo.&lt;br&gt;- Paciente con una neoplasia conocida, o antecedentes de neoplasia en los últimos 5 años, excepto carcinoma cutáneo localizado de células basales o escamosas que haya sido tratado con éxito.&lt;br&gt;- Hallazgos anormales de importancia clínica, ya sea en las evaluaciones físicas o en las pruebas de laboratorio, efectuados en las 2 semanas previas a la administración de la primera dosis de Certican® y que, a juicio del investigador, podrían interferir con los objetivos del estudio.&lt;br&gt;- Mujeres en periodo de lactancia.&lt;br&gt;- Paciente con síntomas de enfermedad somática o mental significativa, o con historia no resuelta de abuso de drogas o alcohol.&lt;br&gt;- Paciente que no coopera ni se comunica con el investigador.&lt;br&gt;&lt;br&gt;&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>Transplante renal de novo

de novo kidney transplantation</Condition>
    <Intervention>&lt;br&gt;Trade Name: Certican&lt;br&gt;Product Name: Certican&lt;br&gt;Product Code: RAD001  &lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.25-&lt;br&gt;&lt;br&gt;Trade Name: Certican&lt;br&gt;Product Name: Certican&lt;br&gt;Product Code: RAD001&lt;br&gt;Pharmaceutical Form: Dispersible tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0,1-&lt;br&gt;&lt;br&gt;Trade Name: Certican&lt;br&gt;Product Name: Certican&lt;br&gt;Product Code: RAD001  &lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0.50-&lt;br&gt;&lt;br&gt;Trade Name: Certican&lt;br&gt;Product Name: Certican&lt;br&gt;Product Code: RAD001  &lt;br&gt;Pharmaceutical Form: Tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 1-&lt;br&gt;&lt;br&gt;Trade Name: Certican&lt;br&gt;Product Name: Certican&lt;br&gt;Product Code: RAD001&lt;br&gt;Pharmaceutical Form: Dispersible tablet&lt;br&gt;INN or Proposed INN: Everolimus&lt;br&gt;Concentration unit: mg milligram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0,25-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: El objetivo primario es determinar si la reducción de la dosis de tacrolimus puede preservar la función renal en pacientes receptores de trasplantes renales de novo que reciben tacrolimus además de Certican®, AR IL-2 y corticosteroides. Este objetivo se valorará comparando la función renal evaluada a los 12 meses de realizado el trasplante a través de una tasa de filtrado glomerular (GFR) calculada (fórmula MDRD) entre dos grupos de pacientes que reciben dos diferentes niveles de exposición al tacrolimus.&lt;br&gt;&lt;br&gt;;Secondary Objective: El objetivo secundario principal es evaluar la eficacia de los dos regímenes. Esto se evaluará con la comparación entre los dos grupos de la incidencia de rechazo agudo confirmado por biopsia (RACB), desde el Mes 4 hasta el Mes 12 después del trasplante. &lt;br&gt;Los otros objetivos secundarios son evaluar la eficacia y la seguridad de los dos regímenes. Esto se evaluará a los 12 meses, efectuando una comparación entre los dos grupos.&lt;br&gt;;Primary end point(s): La función renal se evaluará a los doce meses post-transplante por la creatinina sérica, el aclaramiento de creatinina calculado (fórmula de Cockcroft-Gault), la GFR calculada (fórmula de MDRD y fórmula de Nankivell). También se evaluará la proteinuria cuantitativa. </Primary_outcome>
    <Secondary_ID>CRAD001A2426</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2456453</Internal_Number>
    <TrialID>EUCTR2005-005972-34-DK</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Retrograd intrarenal stenkirurgi. En metode til behandling af den ESWL-resistente nyresten - Retrograde intrarenal Stone Surgery</Public_title>
    <Scientific_title>Retrograd intrarenal stenkirurgi. En metode til behandling af den ESWL-resistente nyresten - Retrograde intrarenal Stone Surgery                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                </Scientific_title>
    <Primary_sponsor>Fredericia Hospital</Primary_sponsor>
    <Date_registration3>20060105</Date_registration3>
    <Date_registration>05/01/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005972-34                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>Yes</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>22/03/2006</Date_enrollement>
    <Target_size>30</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: no&lt;br&gt;Single blind: no&lt;br&gt;Double blind: yes&lt;br&gt;Parallel group: no&lt;br&gt;Cross over: no&lt;br&gt;Other: no&lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: yes&lt;br&gt;Other specify the comparator: saline irrigation fluid as usually used in this kind of procedures &lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Stone surgery required&lt;br&gt;Age &gt; 18 years&lt;br&gt;&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Previous coronary infarct&lt;br&gt;Use of alpha-blocking or beta-blocking drugs&lt;br&gt;Untreated hypertension&lt;br&gt;Ureteral stone&lt;br&gt;Malignant disase in the upper urinary tract&lt;br&gt;Pregnancy&lt;br&gt;</Exclusion_Criteria>
    <Condition>kidney stone</Condition>
    <Intervention>&lt;br&gt;Trade Name: Isoprenalin&lt;br&gt;Product Name: isoprenalin&lt;br&gt;Product Code: 5115&lt;br&gt;Pharmaceutical Form: Concentrate for solution for infusion&lt;br&gt;Current Sponsor code: HJ1&lt;br&gt;Other descriptive name: isoprenalin&lt;br&gt;Concentration unit: µg microgram(s)&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 0,1-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To lower the intrarenal pelvic pressure during retrograde intrarenal stone surgery by adding isoprenalin to the irrigation fluid during the operation.;Secondary Objective: To shorten surgical time in retrograde intrarenal stone surgery whilst optimizing security and quality of the procedure. To spare the kidney parenchyma  from high pressures.;Primary end point(s): Lowering of the renal pelvic pressure.&lt;br&gt;Making the procedure easier for the surgeon (=shorter duration of operation time, fewer complications)</Primary_outcome>
    <Secondary_ID>HJ1</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2456484</Internal_Number>
    <TrialID>EUCTR2006-000753-22-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>A phase I/II feasability trial to assess the safety, immunological activity and efficacy of TroVax plus interferon alpha in patients with advanced or metastatic renal cell cancer.</Public_title>
    <Scientific_title>A phase I/II feasability trial to assess the safety, immunological activity and efficacy of TroVax plus interferon alpha in patients with advanced or metastatic renal cell cancer.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             </Scientific_title>
    <Primary_sponsor>Oxford MioMedica UK Ltd.</Primary_sponsor>
    <Date_registration3>20060410</Date_registration3>
    <Date_registration>10/04/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-000753-22                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>04/05/2006</Date_enrollement>
    <Target_size>10</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: no&lt;br&gt;Randomised: no&lt;br&gt;Open: no&lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Locally advanced or metastatic, histologically proven clear cell or papillary cell renal&lt;br&gt;carcinoma.&lt;br&gt;&lt;br&gt;If previously treated at least four weeks from any previous therapy (except Interferon a) for renal cancer includi,ng surgery chemotherapy, immunotherapy, or radiotherapy. (Patients receiving interferon a whose renal cancer is stable may also be included in the study)&lt;br&gt;&lt;br&gt;Newly diagnosed or progressive of stable measurable disease as defined by the&lt;br&gt;RECIST criteria&lt;br&gt;&lt;br&gt;Patients receiving first or second line treatment for locally advanced or metastatic renal cancer.&lt;br&gt;&lt;br&gt;Patients on stable doses of bisphosphonates that show subsequent tumor progression may continue on this medication; however, patients are not allowed to initiate bisphosphonate therapy within one month prior to starting therapy or throughout the study.&lt;br&gt;&lt;br&gt;Patients must be well enough to tolerate first or second line immunotherapy with&lt;br&gt;interferon alpha.&lt;br&gt;&lt;br&gt;Measurable disease.&lt;br&gt;&lt;br&gt;Aged 18 years or more.&lt;br&gt;&lt;br&gt;Patients must comply with 2 out of 3 of the following:&lt;br&gt;a. Karnofsky score greater than or equal to  80%.&lt;br&gt;b. Haemoglobin concentration greater than or equal to  13g/dL (males) or 11.5 g/dL (females)&lt;br&gt;c. Corrected calcium less than or equal to 10 g/dL (2.5 mmols/L).&lt;br&gt;&lt;br&gt;Clinically immunocompetent.&lt;br&gt;&lt;br&gt;Free of clinically apparent autoimmune disease (including no prior confirmed diagnosis or treatment for autoimmune disease including Systemic Lupus Erythematosis, Grave's disease, Hashimoto's thyroiditis, multiple sclerosis, insulin dependant diabetes mellitus or systemic (non-joint) manifestations of rheumatoid disease).&lt;br&gt;&lt;br&gt;Total white cell count greater than or equal to 3 x 10e9/L and lymphocyte count greater than or equal to 1 x 10e9/dL.&lt;br&gt;&lt;br&gt;Serum creatinine up to 1.5 times upper limit of normal.&lt;br&gt;&lt;br&gt;ALT, AST and bilirubin &lt; 2 times the upper limit of normal.&lt;br&gt;&lt;br&gt;Able to give written informed consent and to comply with the protocol.&lt;br&gt;&lt;br&gt;Women must be either post menopausal, or rendered surgically sterile or, if of child&lt;br&gt;bearing potential, must have been practising a reliable form of contraception (oral&lt;br&gt;contraception + a barrier method) for at least three months prior to the first dose of&lt;br&gt;TroVax and must continue while they are being treated with TroVax. Men must&lt;br&gt;practise a reliable form of contraception while they are being treated with TroVax.&lt;br&gt;&lt;br&gt;No acute changes on 12-lead ECG.&lt;br&gt;&lt;br&gt;No clinical suspicion that cardiac ejection fraction is less than 45% (If clinically&lt;br&gt;suspicion exists the ejection fraction should be measured according to local site&lt;br&gt;procedures)&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Serious infections within the 28 days prior to entry to the trial.&lt;br&gt;&lt;br&gt;Prior TroVax&lt;br&gt;&lt;br&gt;Patients that initiate bisphosphonate therapy within one month prior to starting therapy or throughout the study.&lt;br&gt;&lt;br&gt;Already completed prior second line therapy for advanced or metastatic renal cancer.&lt;br&gt;(Note however that patients currently receiving interferon as second line therapy for&lt;br&gt;advanced or metastatic renal cancer who are stable (ie do not demonstrate response or progression by RECIST criteria) may enter the study)&lt;br&gt;&lt;br&gt;Major surgery or radiation therapy completed less than or equal to 4 weeks prior to enrollment.&lt;br&gt;&lt;br&gt;Prior radiopharmaceuticals (strontium, samarium) within 8 weeks prior to enrollment.&lt;br&gt;&lt;br&gt;Participation in any other clinical trial of a licensed or unlicensed drug within the&lt;br&gt;previous 30 days. (except sorafanib or sutnitinib who may enter the study after 7 days discontinuation)&lt;br&gt;&lt;br&gt;Cerebral metastesis on MRI scan&lt;br&gt;&lt;br&gt;"Currently active" second malignancy, other than non-melanoma skin cancer. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are considered by their physician to be at least less than 30% risk of relapse.&lt;br&gt;&lt;br&gt;Serious intercurrent infections or nonmalignant medical illnesses that are uncontrolled.&lt;br&gt;&lt;br&gt;Psychiatric illnesses/social situations that would limit compliance with protocol&lt;br&gt;requirements.&lt;br&gt;&lt;br&gt;Creatinine 21.5 x ULN.&lt;br&gt;&lt;br&gt;Chronic oral corticosteroid use unless prescribed as replacement therapy in the case&lt;br&gt;of adrenal insufficiency.&lt;br&gt;&lt;br&gt;Clinical indication of reduced cardiac function or an ejection fraction of r 40%.&lt;br&gt;&lt;br&gt;Requirement for radiotherapy (this is a sign of disease progression and is classed as a withdrawal criterion).&lt;br&gt;&lt;br&gt;Concurrent chemotherapy, immunotherapy and radiation therapy&lt;br&gt;&lt;br&gt;No investigational or commercial agents or therapies other than those included in protocol treatment may be administered with the intent to create regression of the&lt;br&gt;patient's malignancy.&lt;br&gt;&lt;br&gt;Life threatening illness unrelated to cancer.&lt;br&gt;&lt;br&gt;Cerebral metastases on MRI scan.&lt;br&gt;&lt;br&gt;History of allergic response to previous vaccinia vaccinations.&lt;br&gt;&lt;br&gt;Participation in any other clinical trial of a licensed or unlicensed drug within the&lt;br&gt;previous 30 days or during the course of this trial.&lt;br&gt;&lt;br&gt;Previous malignancies within the last 10 years other than successfully treated&lt;br&gt;squamous carcinoma of the skin or in situ carcinoma of the cervix treated with cone&lt;br&gt;biopsy.&lt;br&gt;&lt;br&gt;Previous history psychosis or of major a psychiatric disorder requiring hospitalization or any current psychiatric disorder that would impede the patient's ability to provide&lt;br&gt;informed consent or to comply with the protocol.&lt;br&gt;&lt;br&gt;Known allergy to egg proteins.&lt;br&gt;&lt;br&gt;Known to test positive for HIV or hepatitis B or C.&lt;br&gt;&lt;br&gt;Pregnancy or lactation.&lt;br&gt;&lt;br&gt;Prior history of organ transplantation.&lt;br&gt;</Exclusion_Criteria>
    <Condition>Advanced or Metastatic Renal Cell Cancer</Condition>
    <Intervention>&lt;br&gt;Product Name: TroVax&lt;br&gt;Product Code: TV&lt;br&gt;Pharmaceutical Form: Suspension for injection&lt;br&gt;Current Sponsor code: TroVax&lt;br&gt;Concentration type: range&lt;br&gt;Concentration number: 1.58 x 10e8-1.58 x 10e9&lt;br&gt;&lt;br&gt;Trade Name: Roferon-A&lt;br&gt;Product Name: Roferon-A&lt;br&gt;Pharmaceutical Form: Solution for injection&lt;br&gt;INN or Proposed INN: Interferon A&lt;br&gt;Concentration unit: IU/ml international unit(s)/millilitre&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 18 x 10e6-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Secondary Objective: Though this is a phase I/II feasibility study to assess the safety and immunological&lt;br&gt;activity of TroVax combined with IFN-a, tumour response in each patient will also&lt;br&gt;be evaluated using RECIST criteria.;Main Objective: To evaluate whether IFN-a markedly increases the cellular or humoral anti-5T4&lt;br&gt;response to TroVax compared to that observed in previous studies using TroVax&lt;br&gt;alone, in combination with IL-2 or with chemotherapy.;Primary end point(s): Immunology endpoints&lt;br&gt;Antibody response to 5T4 as measured by ELISA&lt;br&gt;Cellular response to 5T4 antigen as measured by lFN gamma Elispot&lt;br&gt;&lt;br&gt;Primary safety endpoints&lt;br&gt;Assessment of the number of adverse events and serious adverse events&lt;br&gt;Assessment of safety by analysis of clinical laboratory variables (complete blood&lt;br&gt;count and chemistry panel).&lt;br&gt;&lt;br&gt;Efficacy endpoint&lt;br&gt;Tumour outcomes will be reported according to RECIST criteria.</Primary_outcome>
    <Secondary_ID>TV2/003/06</Secondary_ID>
  </Trial>
  <Trial>
    <Internal_Number>2456489</Internal_Number>
    <TrialID>EUCTR2005-005809-38-GB</TrialID>
    <Last_Refreshed_on>19 March 2012</Last_Refreshed_on>
    <Public_title>Does prophylactic N acetylcysteine reduce the incidence of contrast nephropathy in patients undergoing peripheral angiography - NAC as a Nehroprotective agent in Peripheral Angiography</Public_title>
    <Scientific_title>Does prophylactic N acetylcysteine reduce the incidence of contrast nephropathy in patients undergoing peripheral angiography - NAC as a Nehroprotective agent in Peripheral Angiography                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </Scientific_title>
    <Primary_sponsor>Research &amp; Development Department, Addenbrookes Hospital</Primary_sponsor>
    <Date_registration3>20060110</Date_registration3>
    <Date_registration>10/01/2006</Date_registration>
    <Export_date>7/29/2014 2:35:16 AM</Export_date>
    <Source_Register>EU Clinical Trials Register</Source_Register>
    <web_address>https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-005809-38                                                                                                                                                                    </web_address>
    <Recruitment_Status>Authorised</Recruitment_Status>
    <other_records>No</other_records>
    <Inclusion_agemin />
    <Inclusion_agemax />
    <Inclusion_gender>&lt;br&gt;Female: yes&lt;br&gt;Male: yes&lt;br&gt;</Inclusion_gender>
    <Date_enrollement>08/12/2006</Date_enrollement>
    <Target_size>40</Target_size>
    <Study_type>Interventional clinical trial of medicinal product</Study_type>
    <Study_design>Controlled: yes&lt;br&gt;Randomised: yes&lt;br&gt;Open: yes&lt;br&gt;Single blind: &lt;br&gt;Double blind: &lt;br&gt;Parallel group: &lt;br&gt;Cross over: &lt;br&gt;Other: &lt;br&gt;If controlled, specify comparator, Other Medicinial Product: no&lt;br&gt;Placebo: no&lt;br&gt;Other: no&lt;br&gt;</Study_design>
    <Inclusion_Criteria>Inclusion criteria: &lt;br&gt;Any patient undergoing peripheral angiography in the Cambridge Vascular Unit, Addenbrooke’s Hospital, Cambridge who consents to participation&lt;br&gt;Are the trial subjects under 18? no&lt;br&gt;Number of subjects for this age range: &lt;br&gt;F.1.2 Adults (18-64 years) yes&lt;br&gt;F.1.2.1 Number of subjects for this age range &lt;br&gt;F.1.3 Elderly (&gt;=65 years) yes&lt;br&gt;F.1.3.1 Number of subjects for this age range &lt;br&gt;</Inclusion_Criteria>
    <Exclusion_Criteria>Exclusion criteria: &lt;br&gt;Any patient undergoing peripheral angiography in Cambridge Vascular Unit, &lt;br&gt;Any patient that does not consent to participation in the study.&lt;br&gt;Any patient under the age of 18 years&lt;br&gt;Any patient with established renal failure on renal replacement therapy (dialysis).&lt;br&gt;&lt;br&gt;</Exclusion_Criteria>
    <Condition>We will use N acetylcystiene prophylactically in patient undergoing peripheral angiography at the Cambridge Vascular Unit at Addenbrooke's Hospital in order to prevent renal injury. Patients undergoing peripheral angiography have large quanities of contrast medium injected intravenously, contrast medium is a nephrotoxic substance. Thge drug will be administrated prophylactically to aviod acute renal failure.</Condition>
    <Intervention>&lt;br&gt;Trade Name: Fluimucil&lt;br&gt;Pharmaceutical Form: Effervescent tablet&lt;br&gt;INN or Proposed INN: N acetylcysteine&lt;br&gt;Concentration unit: mg/kg milligram(s)/kilogram&lt;br&gt;Concentration type: equal&lt;br&gt;Concentration number: 600-&lt;br&gt;&lt;br&gt;</Intervention>
    <Primary_outcome>Main Objective: To investigate the role of N acetylcysteine as a nephroprotective agent in patients undergoing peripheral angiography at Addenbrooke’s Hospital, Cambridge.&lt;br&gt;&lt;br&gt;Primarily we are looking for a reduction in the elevation of serum creatinine and also of other markers of renal damage in urine (retinol binding protein and albumin)&lt;br&gt;&lt;br&gt;A reduction in the mortality and morbidity related to renal failure that may result from a contrast medium induced nephropathy.&lt;br&gt;;Secondary Objective: ;Primary end point(s): To obtain eveidence that shows prophylactic use of N acetylcysteine is significantly nephroprotective for patients undergoing peripheral angiography</Primary_outcome>
    <Secondary_ID>NACP1</Secondary_ID>
  </Trial>
</Trials_downloaded_from_ICTRP>